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OBJECTIVES
Development of a high performance liquid chromatographic 
method for the separate detection of benzimidazoles and 
their principal metabolites.
Evaluation of the reproducibility of the method using 
spiked tissue, milk and plasma samples.
Investigation of benzimidazole concentrations in plasma, 
tissues and milk of animals treated, from the day of 
administration until residues can no longer be detected.
To assess if the recommended withdrawal periods are 
adequate and, by means of an abattoir survey, if 
benzimidazole residues pose a problem to the consumer.
SUMMARY
A high performance liquid chromatographic method for the separate 
detection of benzimidazole anthelmintics and their principal
metabolites has been developed, and an evaluation was made of the 
reproducibility of the method using spiked tissue, milk and plasma 
samples. In addition, an investigation of benzimidazole concentrations 
in tissues, milk and plasma of treated animals was carried out, from 
the day of administration until residues could no longer be detected, 
to assess if the recommended withdrawal periods were adequate and, by 
means of an abattoir survey, if benzimidazole residues pose a problem 
to the consumer. The animals used were cattle and sheep, and the drugs 
used were febantel (a pro-benzimidazole), and the benzimidazoles, 
albendazole, fenbendazole, oxfendazole and thiabendazole.
For all of the drugs studied residues were found in tissues.
Relatively high concentrations of benzimidazoles and metabolites were
found in liver compared with plasma or other tissues. Detectable 
residues of febantel, fenbendazole, oxfendazole and thiabendazole in
liver persisted beyond the recommended withdrawal periods. In muscle, 
residues of all the drugs studied were low, being similar to those 
found in plasma.
None of the sulphide benzimidazoles (albendazole and 
fenbendazole) were detectable in milk at any time after administration 
to cows and only sulphoxides (oxfendazole and albendazole sulphoxide) 
and sulphones (oxfendazole sulphone and albendazole sulphone) were
detectable.
In an abattoir survey of cattle and sheep carcasses, no residues 
of any of these drugs were detected in one hundred livers analysed.
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The Ministry of Agriculture, Fisheries and Food in the United 
Kingdom is charged through the Veterinary Products Committee under the 
Medicines Act with the duty of ensuring that food does not contain 
residues of drugs or other contaminants which may be harmful to the 
consumer. Currently in the EEC there is a programme for monitoring 
antibiotic residues in milk, and programmes are being developed for the 
detection of antibiotics and non-natural hormones in meat.
Apart from antibiotics and hormones, anthelmintics are the most 
commonly used drugs in cattle and sheep in the United Kingdom, with 
animals being treated on average two to three times a year.
This study was designed to devise methods for the measurement of 
residues of benzimidazoles and pro-benzimidazoles and also to assess 
any residue problem that may exist.
The benzimidazoles and pro-benzimidazoles are a major group of 
anthelmintics, with sales which account for more than fifty per cent of 
the total UK market for anthelmintics (1984). It may be argued that 
residues of these anthelmintics would not pose a problem, as it is
unlikely that any farmer would dose his animals at some expense (more
than one pound per head of cattle and around fifteen pence per sheep)
if they were to be slaughtered soon after treatment. However, there are 
always casualty animals, and also some residues have been found to be 
long-lived (see later) and therefore, residues may pose a problem.
Possibly a greater problem would be residues of other drugs such as 
salicylanilide flukicides, which may persist for as long as three
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months (Mohammed-Ali, 1985). In addition, the use of anthelmintics in 
boluses, either slow-release or pulsed release, enhances the risk of an 
animal at slaughter having measurable residues. Indeed, a pulsed 
release oxfendazole bolus with five pulses at twenty-one day intervals 
has recently been licenced (1986).
Other groups of anthelmintics available include the avermectins 
(ivermectin), the imidazothiazoles (levamisole, morantel and pyrantel), 
the salicylanilides and substituted phenols (closantel, rafoxanide, 
oxyclozanide, nitroxynil and brotianide), piperazines
(diethylcarbamazine) and others (arecoline, bunamidine and
praziquantel).
BENZIMIDAZOLES AND PRO-BENZIMIDAZOLES - BACKGROUND
Thiabendazole was introduced almost twenty-five years ago (Brown 
et al., 1961). It was the first broad-spectrum anthelmintic, which was 
later used as an agricultural fungicide and also as an anthelmintic in 
man.
The introduction of thiabendazole resulted in a considerable 
amount of research being carried out with benzimidazoles. As a result, 
a series of new benzimidazoles and pro-drugs appeared on the market.
The next benzimidazole to appear on the market was parbendazole 
(Actor et al., 1967), followed by cambendazole (Hoff et al., 1970),
mebendazole (Brugman et_al., 1971), oxibendazole (Theodorides et al.,
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1973), fenbendazole (Baeder et al., 1974), oxfendazole (Averkin et al.t 
1975) and albendazole (Theodorides et al., 1976).
The earlier benzimidazoles were thiabendazole analogues and the 
more recent ones are benzimidazole carbamates (Table 1.1). They are all 
used as veterinary anthelmintics except carbendazim (the parent 
benzimidazole carbamate, i.e. unsubstituted on the benzene ring), 
ciclobendazole (which is not commercially available) and oncodazole 
(which is an experimental anti-cancer drug).
Halogenated benzimidazole analogues have been reported which have 
flukicidal activity. However, none of these compounds are used 
commercially, with the exception of triclabendazole which has recently 
appeared on the market (Boray et al., 1983).
Numerous pro-drugs can also lead to the formation of 
benzimidazoles via hydrolytic or cyclization processes. For example, 
benomyl (Watkins, 1976) is hydrolysed to carbendazim and similarly 
there is a pro-drug which hydrolyses to oxfendazole (Hennessy et al., 
1983). Ketal derivatives of flubendazole and mebendazole have also been 
reported (Michiels et al., 1982).
Benzimidazole carbamate synthesis usually involves a cyclization 
reaction. This reaction has been utilised in the design of pro-drugs 
which may be converted chemically and/or metabolically to the 
anthelmintically active benzimidazole. Originally, the thiophanates 
were developed for use as fungicides, but the ethyl analogue is also
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anthelmintically active. Cyclization is the process by which the 
thiophanates are metabolically converted to carbendazim or its ethyl 
analogue. The mechanism of this cyclization reaction is poorly 
understood. According to Douch (1974) this reaction is mono-oxygenase 
dependent. McDougall et al.t (1985) suggest that netobimin (a novel 
anthelmintic which is a pro-drug of albendazole) undergoes cyclization 
to albendazole in the liver and is converted (oxidized) to albendazole 
sulphoxide in the rumen. However, it has been observed (Bogan and 
Marriner, unpublished) that cyclization occurs in the rumen to a 
greater extent, with only very small amounts of albendazole sulphoxide 
being present compared to the amount of albendazole. The rumen is
considered to be a purely reductive medium (Prins, 1985) and it has
been demonstrated (see later) that albendazole sulphoxide is reduced to
albendazole to a great extent in the rumen. A pro-drug of mebendazole
has also been reported (Dawson et al., 1983) which is absorbed
unchanged from the gastro-intestinal tract of the rat, resulting in 
higher blood concentrations of mebendazole than those achieved when 
mebendazole is administered at the same dose rate.
Febantel (a commercially available pro-benzimidazole 
anthelmintic) follows a similar pattern to that of the thiophanates. 
Hydrolysis results in the removal of a methoxyacetyl group and this is 
followed by cyclization to a benzimidazole (fenbendazole) (Delatour et 
al., 1982b).
There are many examples of compounds which convert metabolically 
and/or hydrolytically to active benzimidazoles. The more complex
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pro-drug, netobimin, undergoes metabolic reduction of a nitro group to 
an amino group before cyclizing to a benzimidazole (albendazole).
MODE OF ACTION OF BENZIMIDAZOLES
Several mechanisms of action have been proposed for benzimidazole 
anthelmintics : inhibition of the uptake of low molecular weight 
compounds (including glucose) by susceptible parasites (Van den 
Bossche, 1972; Van den Bossche and de Nollin, 1973)2 inhibition of 
fumarate reductase (Kohler and Bachmann, 1978; Prichard, 1973) and 
disruption of cytoplasmic microtubules in intestinal cells (Borgers et 
al., 1975; Van den Bossche, 1976).
Other studies have demonstrated that benzimidazoles are active 
against parasite embryos. However, the mode of embryotoxic action has 
not been determined (Coles and McNeillie, 1977; Samizadeh-Yazd and 
Todd, 1978).
The use of competitive colchicine binding studies and 
turbidimetric techniques has shown that benzimidazoles have an 
inhibitory effect on the polymerisation of tubulin into microtubules. 
These studies have been carried out on tubulin from rat brain (Hoebeke 
et al., 1976), sheep brain (Ireland et al., 1979), calf brain (Friedman 
and Platzer, 1978; Laclette et al., 1980; Lee et al., 1980) and pig
brain (Kohler and Backmann, 1981). Benzimidazoles bind to the same site 
on the protein as colchicine does. Pre-incubation of tubulin in the 
presence of benzimidazoles inhibits the binding of colchicine
(Barrowman et al., 1984a). Inhibition of colchicine binding is
generally competitive, although cambendazole shows non-competitive 
binding (Friedman and Platzer, 1978). Binding of benzimidazoles to 
tubulin is also saturable and reversible, with one binding site per 
tubulin dimer. This is also true for colchicine. Pre-formed 
microtubules are not affected in vitro by benzimidazoles (Hoebeke et 
al., 1976). Benzimidazoles also bind to nematode tubulin, which has a
greater affinity (384 times greater) for benzimidazoles than mammalian 
tubulin derived from bovine brain (Friedman and Platzer, 1980). 
However, other investigators have only shown the binding of 
benzimidazoles to be two-fold greater than binding to pig brain tubulin 
(Kohler and Bachman, 1981).
A great deal of evidence has accumulated to suggest that - 
inhibition of fumarate reductase or interference with glucose uptake 
are not the modes of action common to all benzimidazoles (Coles, 1977; 
Van den Bossche, 1978). It seems likely that microtubule inhibition is 
the major effect; inhibition of fumarate reductase and interference 
with glucose uptake occurring as a result of microtubule inhibition 
(Barrowman et al., 1984b).
It has been postulated that all the benzimidazole anthelmintics 
have the same mode of action and that differences in efficacy and 
spectrum of activity between different benzimidazoles are due to 
differences in the pharmacokinetic behaviour of the drugs (Prichard et_ 
al., 1978). This view is strengthened by the fact that the newer, more
potent benzimidazoles (albendazole, fenbendazole and oxfendazole) are
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much more slowly absorbed and eliminated than the earlier 
benzimidazoles (i.e. thiabendazole). For example, after oral
administration of thiabendazole to sheep, its maximum plasma
concentration is reached after four hours (Tocco et al., 1964). In
comparison, after oral administration of fenbendazole and oxfendazole 
to sheep, maximum plasma concentrations occur after twenty-four hours 
(Marriner and Bogan, 1981a, 1981b) and after oral administration of
albendazole to sheep, maximum concentrations occur at fifteen hours 
(Marriner and Bogan, 1980). It has also been shown (Prichard et al.,
1978) that thiabendazole is effective against inhibited larvae of 
Ostertagia ostertagi when it is continuously infused over a long period 
of time, whereas thiabendazole as a single dose has previously been 
shown to be ineffective against inhibited larvae (Armour, 1969; Armour 
et al.. 1975; Anderson, 1977). Thus it has been suggested that
variations in efficacy are due not only to the concentration of 
anthelmintic to which the parasite is exposed but also to the duration 
of exposure of the parasite to a toxic concentration.
TOXICITY OF BENZIMIDAZOLES
Benzimidazole anthelmintics have an unusually low degree of acute 
toxicity to mammals for drugs which have such a broad spectrum of 
activity against parasitic helminths. Even with the more acutely toxic 
benzimidazoles (e.g. albendazole), the no-effect level is six times the 
normal therapeutic dosage (Johns and Philip, 1977), and therefore, in 
field use, toxicity has never been recorded. In experimental animals 
receiving repeated doses, toxic effects are non-specific
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(i.e. anorexia, lethargy). Data on the acute toxicity of some of the 
benzimidazoles is difficult to find, since most of it is "in house" 
data, and since there are no published reports of accidental toxicity 
in field use.
The greatest toxicity risk of benzimidazoles is teratogenicity, 
which is known to occur with parbendazole, cambendazole, oxfendazole 
and albendazole, at dose rates lower than those which produce acute 
toxicity.
Parbendazole is teratogenic in the rat and the sheep, although in 
laboratory studies, its combination with SKF-525A (an inhibitor of 
microsomal oxidation) shows that parbendazole itself is relatively 
non-toxic (Delatour, 1983). It is a hydroxy-metabolite which is 
responsible for its toxicity (Di Cuollo et al., 1974).
Cambendazole has also been shown to be teratogenic in the rat and 
the sheep (Delatour et al., 1975).
Fenbendazole is not teratogenic in any species, probably due to 
the fact that it is very insoluble and therefore, no matter how much is 
administered, not enough can dissolve to produce blood concentrations 
high enough to cause teratogenicity. Its sulphoxide metabolite 
(oxfendazole) has been identified in the rat (Becker, 1976), in the 
milk of cows (Delatour, 1983) and in sheep (Marriner and Bogan, 1981b) 
treated with fenbendazole. Oxfendazole is teratogenic in the rat and 
the sheep.
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Albendazole has been extensively studied with regard to its 
teratogenic potential (Delatour et al., 1984). Metabolic studies have 
allowed the isolation of numerous metabolites (Gyurik et al., 1981), 
all of which have been investigated in the rat for their 
embryotoxicity. Both albendazole itself and its sulphoxide metabolite 
are teratogenic in the rat. Treatment with albendazole combined with 
SKF-525A eliminates the teratogenic effects of albendazole. Martin 
(1980) suggested that the product responsible for the teratogenicity of 
albendazole is the sulphoxide metabolite or a close derivative which is 
not the sulphone metabolite. Although "treatment with albendazole 
combined with SKF-525A eliminates the teratogenic effects of 
albendazole, this may be due to decreased bioavailability of 
albendazole in the presence of SKF-525A, rather than inhibition of 
enzymatic S-oxidation (Delatour et al., 1984).
Febantel (a pro-benzimidazole) is teratogenic in the rat. Studies 
have shown that in vivo, febantel cyclizes to fenbendazole and 
oxfendazole. The combination of febantel with SKF-525A inhibits 
febantel toxicity in the rat. Therefore, the embryotoxicity of febantel 
is probably caused by its metabolite oxfendazole (Delatour et al. , 
1982).
Febantel is not teratogenic in the sheep at therapeutic doses, 
but since its metabolism is similar in the rat and the sheep, it is 
likely that it would be teratogenic in the sheep at higher dose levels.
10
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CHAPTER 2
AN ASSESSMENT OF THE RISK OF RESIDUES
Risk assessment is the scientific process by which the toxic 
properties of a substance are identified and evaluated. This process 
determines the likelihood that humans exposed to the substance will be 
adversely affected, and characterizes the nature of the effects they 
may experience. Using this information, the regulatory authorities can 
then make a judgement about whether exposure to the substance under 
certain defined conditions can be considered acceptable or safe.
For all substances (drugs and other environmental substances), 
the first step in risk assessment is the collection of toxicity 
information. This data includes basic knowledge about the properties of 
the substance and its effects in various biological systems. The 
necessary information comes from a variety of sources, but much of it 
is derived from studies in animals.
If any toxic effects noted in animals at various dose rates are 
deemed relevant to those which might occur in humans, the next step in 
risk assessment generally involves identifying the highest dose at
which no adverse effects are observed in the animals, and dividing that 
dose by a safety factor (usually 100). This calculation yields an 
exposure level called the acceptable daily intake (ADI), which is
considered to be a safe level of exposure for humans.
An ADI is defined as the amount of toxicant in milligrams per
kilogram body weight per day (or in milligrams per day for a 70 kg 
person) which is not anticipated to result in any adverse effects after 
chronic exposure to the general population of humans, including
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sensitive sub-groups. Adverse effects are considered as functional 
impairment or pathological lesions which may affect the performance of 
the whole organism, or which reduce an organism’s ability to respond to 
an additional challenge (U.S. EPA, 1980). Operationally, ADIs are 
calculated by dividing a NOEL, NOAEL or LOAEL (derived from human or 
animal toxicity studies) by one or more uncertainty factors (safety 
factors).
ADI = ’’no-effect” level 
uncertainty factor
NOEL (no-observed-effect level) is that dose of a chemical at which 
there are no statistically or biologically significant increases in 
frequency or severity of effects between the exposed population and its 
appropriate control.
NOAEL (no-observed-adverse-effect level) is that dose of a 
chemical at which there are no statistically or biologically 
significant increases in frequency or severity of adverse effects 
between the exposed population and its appropriate control. Effects are 
produced at this dose, but they are not considered to be adverse.
LOAEL (lowest-observed-adverse-effect level) is the lowest dose 
of a chemical in a study or group of studies which produces 
statistically or biologically significant increases in frequency or 
severity of adverse effects between the exposed population and its 
appropriate control.
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Scientific guidelines and recommendations on the use of ADIs have 
been adopted by several international bodies including the Food and 
Drug Administration (FDA), the U.S. Environmental Protection Agency 
(U.S. EPA) and the joint Food and Agricultural Organisation/World 
Health Organisation (FAO/WHO) Food Standards Programme. Initial 
publications in this area of regulation suggest that ADIs for food 
additives or contaminants should be derived from a chronic animal NOEL 
or NOAEL (measured in mg/kg of diet) by dividing by a 100-fold 
uncertainty factor (Lehman and Fitzhugh, 1954). These workers reasoned 
that this factor accounted for several areas of uncertainty: 
intra-(human) or inter-(animal to human) species variability in 
response to the toxicity of a chemical, allowance for sensitive human 
sub-populations due to illness as compared to healthy experimental 
animals, and possible synergistic action of any one of the many 
intentional or unintentional food additives or contaminants in the 
human diet.
Similar areas of uncertainty have been addressed by other 
authors. Bigwood (1973) justified the 100-fold uncertainty factor for 
food additives on the basis of differences in body size of the 
laboratory animal versus that of man, differences in food requirements 
varying with age, sex, muscular expenditure and environmental 
conditions within a species, differences in water balance of exchange 
between the body and its environment among species, and differences in 
susceptibility to the toxic effect of a given contaminant among 
species. Other workers (Vettorazzi, 1976 and 1980; Lu, 1979) 
substantiated the use of the 100-fold uncertainty factor by discussing
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differences in susceptibility between animals and humans to toxicants, 
variations in sensitivities in the human population, the fact that the 
number of animals tested is small compared with the size of the human 
population that may be exposed, the difficulty in estimating human 
intake, and the possibility of synergistic action among chemicals 
within the human diet.
Although the specific areas of uncertainty described by these 
authors (Lehman and Fitzhugh, 1954; Bigwood, 1973; Vettorazzi, 1976 and 
1980) to support a 100-fold uncertainty factor differ somewhat, they 
can be generally viewed as being due to intra- or interspecies 
variability. Depending on the adverse effects found, the safety factor 
will be higher or lower than 100. For minor effects, 100 is used. For 
serious adverse effects (e.g. teratogenicity), a higher safety factor 
is used.
BENZIMIDAZOLE TOXICITY
Thiabendazole was introduced in 1961 and was recognized as having 
very low acute toxicity. No problems were encountered in its field 
usage and it was only after the introduction of parbendazole in 1967 
that the toxicity of benzimidazoles was first recognized. It was found 
to be teratogenic at doses lower than those causing acute toxicity and 
as a result all new benzimidazoles have been extensively studied with 
regard to their potential teratogenicity and other genotoxic effects.
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TERATOGENICITY OF BENZIMIDAZOLES
In sheep, many studies have been carried out with parbendazole, 
at dosages ranging from 25 mg/kg to 60 mg/kg. Teratogenicity of 
parbendazole was first demonstrated in sheep (Lapras et al., 1973a; 
Lemon and Hancock, 1974; Middleton et al., 1974; Saunders et al., 1974; 
Shone et al., 1974 and Szabo et al., 1974). The most commonly observed 
effects were skeletal malformations. These effects were later observed 
for cambendazole (Delatour et al.t 1975a), oxfendazole (Delatour et 
al., 1977), albendazole (Johns and Philip, 1977) and febantel (Chement, 
1982), all in sheep.
The benzimidazoles which are teratogenic in sheep do not appear 
to be so in cattle. With parbendazole (Miller et al., 1974). 
fenbendazole (Becker, 1975), oxibendazole (Theodorides et al., 1977),
oxfendazole (Piercy et al., 1979) and albendazole, no malformations
were observed after treatment.
Regarding teratogenicity, pigs have been reported to be 
insensitive to parbendazole (Hancock and Poulter, 1974), oxfendazole 
(Morgan, 1982), mebendazole (Van den Bossche et al., 1982) and
fenbendazole (Anonymous, 1984).
In the horse, teratogenicity was not observed for fenbendazole 
(Becker, 1975), oxfendazole (Anonymous, 1978), oxibendazole (Anonymous, 
1980) or mebendazole (Van den Bossche et al.t 1982). With cambendazole, 
limb malformations were observed in three colts after the treatment of 
mares at an oral dose of 20 mg/kg (Drudge et al.t 1983).
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The rat is the animal species which has been most studied with 
regard to the teratogenicity of benzimidazoles. Embryolethal and 
teratogenic effects have been reported for parbendazole (Lapras et al., 
1973b; Duncan and Lemon, 1974 and Mercier-Parot, 1976), mebendazole and 
cambendazole (Delatour et al., 1974; Fave and Maillet, 1975),
ciclobendazole and carbendazim (Delatour and Richard, 1976b; Minta and 
Biernacki, 1982), oxfendazole (Delatour et al., 1977), albendazole 
(Delatour et al., 1981), febantel (Delatour et al., 1982b), ethyl
1H-benzimidazol-2-yl carbamate (Lemarchands, 1984) and netobimin (a
pro-drug of albendazole) (Delatour et al., 1985b).
Fenbendazole (Baeder et al., 1974) and oxibendazole (Delatour et 
al., 1976c) do not appear to be teratogenic in the rat. Thiabendazole
does not appear to be teratogenic in the rat, although it has been 
reported that minor abnormalities have occurred (retardation of 
ossification of the sternum) at a dose of 500 mg/kg (Khera et al.,
1979).
In the mouse, parbendazole is teratogenic (Lapras et al., 1973c). 
The same abnormalities occur as in the rat, although double the dose is 
required. Thiabendazole has been reported to cause various 
abnormalities, but only at very high doses of between 700 mg/kg and 
2400 mg/kg (Ogata et al., 1982 and 1984; Kubo et al., 1982).
Methyl thiophanate (which is metabolised to carbendazim) is not 
teratogenic in the mouse at a dose of 10 mg/kg/day (Makita et al.,
1973).
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In the hamster, parbendazole is not teratogenic at a dose rate of 
100 mg/kg (Duncan and Lemon, 1974; Lemon and Hancock, 1974). However, 
it has been demonstrated that carbendazim is teratogenic in the hamster 
(Minta and Biernacki, 1982).
In the rabbit, parbendazole and other benzimidazoles are not 
teratogenic (Lapras et al., 1973c). Fenbendazole is embryotoxic but not 
teratogenic in rabbits at a dose rate of 63 mg/kg (Anonymous, 1984).
According to Minta and Biernacki (1982), carbendazim is 
teratogenic in rabbits, but this was not confirmed by Janardhan et al., 
(1984).
GENOTOXICITY OF BENZIMIDAZOLES
Some benzimidazoles have been tested for their possible 
genotoxicity, in bacteria and in rats and mice. These studies have 
involved mostly benomyl and carbendazim, which are considered 
toxicologically important because of their widespread use as 
agricultural fungicides (Sherman et al. 1975). Furthermore, carbendazim 
is a major residue found in plants after benomyl treatment (Clemons and 
Sisler, 1969). The anthelmintics commonly used in veterinary medicine 
have not been studied with respect to their genotoxic effects, possibly 
because some workers consider that human exposure to these compounds is 
of minor importance (Seiler, 1976).
The Dominant Lethal Test has been found to be consistently
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negative for the benzimidazoles and their pro-drugs. This test has been 
carried out using carbendazim in mice at a dosage of 1280 mg/kg (Hofman 
and Peh, 1973), in rats at a dosage of 280 mg/kg (Rideg and Imre, 
1982), mebendazole in mice up to a dosage of 640 mg/kg (Leonard et al.,
1974), benomyl (a pro-drug of carbendazim) added to feed (Sherman et 
al., 1975), cypendazole (Machemer, 1974) and methyl thiophanate up to a 
dosage of 500 mg/kg (Makita et al., 1973).
A positive result to the Mammalian Spot Test (which looks for 
induced genetic alterations in melanoblastic cells) was observed for 
carbendazim in mice at a dose rate of 200 mg/kg on the tenth day after 
conception, although a dose of 100 mg/kg had no effect (Fahrig and 
Seiler, 1979).
Carbendazim and benomyl have been found to be mutagenic in 
Salmonella typhimurium, producing a two to five-fold increase in the 
frequency of mutants in the hisG46 and TA1530 strains (Seiler, 1972 and 
1973). This was confirmed by Kappas et al., (1976). These results were 
controversial because, systematic study of the genotoxicity of benomyl 
and carbendazim showed only low activity on hisG46 strains at 
100 ug/spot of carbendazim (Ficsor et al.t 1978). Using TA1535, TA1536, 
TA1537 and TA1538 strains, benomyl was also found to be inactive at 
20 ug/spot (Carere et al., 1978). Using TA98, TA100, TA1535 and TA1538 
strains, mebendazole was found to be inactive at 1000 ug/plate 
(Paulikova and Dobias, 1981).
Using the Salmonella microsome test, carbendazim and benomyl
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remained active (Ficsor et al., 1978). Using the same test,
thiabendazole had no effect (Fujita and Haraga, 1980a, 1980b and 1981). 
According to Batzinger et al., (1978), mebendazole was active using 
this test, but other workers have shown it to be inactive (Paulikova 
and Dobias, 1981; Cortinas de Nava et al., 1983).
Carbendazim and benomyl were not mutagenic when used in a Rodent 
Host-Mediated Assay in rats and mice (Ficsor et al., 1978). The same 
applied to mebendazole in mice at a dose rate of 125 mg/kg (Paulikova 
and Dobias, 1981) although this has been contradicted (Batzinger et 
al., 1978; Bueding et al., 1979).
In vivo, carbendazim has been shown to induce chromosome 
abnormalities in mouse and hamster bone marrow (Seiler, 1976a),
although its pro-drug methyl thiophanate does not (Makita et al.,
1973). In rats and mice, thiabendazole does not induce chromosomal
abnormalities (Yoshida et al., 1979). The Micronucleus Test has been 
shown to be positive in mice, using carbendazim at doses of 100 mg/kg 
to 1000 mg/kg (Seiler, 1975a), with a dose of 50 mg/kg having no 
effect. Using the Spermatocyte Test and the F1 Translocation Test, 
mebendazole has been shown to give a negative result in mice at dosages 
of 640 mg/kg and 160 mg/kg respectively (Leonard et al.t 1974). Similar 
results have been obtained for methyl thiophanate in rats up to a 
dosage of 1000 mg/kg/day (Makita et al., 1973).
It has been suggested that benzimidazoles are mutagenic in
eukaryotic cells by virtue of their anti-tubule activity. This may lead
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to chromosomal disturbances during mitotic or meiotic anaphase, which 
may lead to numerical aberrations (Schreiner and Holden, 1983). In 
bacteria, benzimidazoles act like abnormal purine bases, which are 
incorporated by RNA-polymerase into the nucleic acids of E.coli, 
replacing guanine (Seiler, 1975c, 1976b and 1978).
ANTIMITOTIC EFFECTS OF BENZIMIDAZOLES
In vivo, cambendazole, mebendazole and parbendazole have been 
shown to be active against ascites carcinoma and leukaemia in mice 
(Lapras et al., 1975; Delatour et al., 1976a; Delatour and Richard,
1976b). Oncodazole was also active in these conditions (Atassi and 
Tagnon, 1975). In dogs, at an oral dose of 50 mg/kg/day, cambendazole 
was active against lymphoid leukosis and mammary adenocarcinoma 
(Delatour et al., 1975b), although tolerance of the drug was low. In 
man, clinical trials were carried out with parbendazole and oncodazole, 
which showed a decrease in the number of malignant cells and resulted 
in the disappearance of ascitic fluid in a patient with carcinoma of 
the stomach (De Brabander et al., 1975a).
In vitro, several models have been used to investigate the 
antimitotic effects of benzimidazoles. These include continuous-line 
cell cultures, primary explant cultures and leucocyte cultures.
Oxfendazole has been shown to have no effect on leucocytes 
(Delatour and Richard, 1976b), a result confirmed by other workers 
(Holden et al., 1980). Oxibendazole has been shown to block leucocyte
division (Delatour and Richard, 1976b). It has also been demonstrated 
that thiabendazole inhibits proliferation of KB and AGMK cells (Mochida 
et al.. 1983), although only at high concentrations.
Oncodazole was tested using embryonic human and murine cutaneous 
fibroblasts, B16 melanoma cells, KB cells, and MO and M04 cells. Using 
concentrations between 0.04 jig/ml and 10 i^g/ral, the cells became 
rounded, the organelles became randomly dispersed and the microtubules 
gradually disappeared (De Brabander et al., 1975a, 1975b and 1976). The 
disappearance of microtubules was later confirmed using parbendazole in 
Vero cells (Havercroft et al., 1981).
OTHER TOXIC EFFECTS OF BENZIMIDAZOLES
Carbendazim has been shown to produce testicular degeneration in 
rats, with abnormalities in spermatogenesis (Styles and Garner, 1974; 
World Health Organisation, 1974; Rideg and Imre, 1982). Mebendazole has 
been shown to cause irreversible testicular degeneration in the rat 
(Anonymous, 1974). Testicular damage did not occur in rats after the 
administration of thiophanates (Makita et al., 1973; Thomas and Schein,
1974). After the administration of fenbendazole, oxfendazole or 
oxibendazole to stallions, it was noted that spermatogenesis was not 
affected (Squires et al., 1978; Anonymous, 1979; Anonymous, 1980).
Many other effects of benzimidazoles have been demonstrated and 
include decrease in milk production (Patton, 1974), decreased 
cholinesterase synthesis (Watts et al., 1982) and alopecia, which has
been observed in sheep after the administration of albendazole (Johns 
and Philip, 1977) and cambendazole (Guilhon and Barnabe, 1973)* 
Alopecia has also been noted in man after mebendazole treatment (Kern 
et al., 1979; Miskovitz and Javitt, 1980; Braithwaite et al., 1982).
BENZIMIDAZOLE RESIDUES : A T0XIC0L0GICAL EVALUATION
In all tests of toxicity described, the benzimidazole being
assessed is freely available in the food of the animal or is freely
dissolved in the in vitro test. However, in any assessment of the risk
of residues, consideration must also be given to whether the residue is
"bio-available", i.e. is readily absorbed when the food containing such 
a residue is consumed.
There is some confusion in the description of residues. Residues 
readily extractable by organic solvents are often called extractable 
residues. Residues which are non-extractable are often called 
tissue-bound residues. However, this may not equate with the likelihood 
of absorbability of residues, for example, a residue could be lightly 
bound, non organic extractable, but on digestion of tissue may or may 
not become free for absorption.
Tissue-bound residues have proven difficult to measure, and as a 
result, indirect methods of toxicological evaluation have been used. 
These are relay-bioavailability (Gallo-Torres, 1975) and relay-toxicity 
(Truhaut and Ferrando, 1975) studies. Relay-bioavailability evaluates 
the absorption of bound residues in animals fed tissues from treated
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animals. Studies with cambendazole (Baer et al., 1977) and albendazole 
(Scott and Dicuollo, 1980) showed that the bioavailability of total 
residues was very low. Relay embryotoxicity studies were carried out in 
pregnant rats which were fed livers containing residues. With 
cambendazole (Baer et al., 1977) and albendazole (Delatour et al.,
1981), relay embryotoxicity did not occur.
Because the binding of residues to tissues is considered to be 
irreversible (Rico and Burgat-Sacaze, 1984), drug residues which are 
covalently bound to tissues should present*little risk to the consumer 
of meat containing these residues. Thus, all these toxicological 
studies with benzimidazoles suggest that the extractable metabolites or 
parent drugs are responsible for the observed toxicity. Therefore, the 
extractable residue fraction in edible tissues is of interest 
toxicologically. The toxic effects of benzimidazoles, which are 
important in the determination of an acceptable daily intake (ADI) of 
residues by humans, are teratogenicity and mutagenicity.
The study of the relationship between metabolism and 
teratogenicity of benzimidazoles allows the differentiation between 
metabolites which are teratogenic and metabolites which are not 
teratogenic, for structural and/or kinetic reasons. It is therefore 
possible to determine which metabolites are the ultimate teratogens. 
For the consumer, it is important to know which metabolites may be 
teratogenic, and also the inactive metabolites which may be 
metabolically converted to teratogenic metabolites. Using the concept 
of "Sum of Potentially Teratogenic Metabolites" (SPTM) it is possible
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to determine the ADI in food. With each drug, the number of metabolites 
which may contribute to the SPTM varies. For example, carbendazim is 
teratogenic in the rat (NOAEL = 9.5 mg/kg). However, its
2-amino-benzimidazole metabolite is not, because it does not have a 
carbamate group which is thought to be necessary for both mutagenic 
(Seiler, 1976a) and teratogenic (Delatour and Richard, 1976b) activity. 
In addition, the 5-hydroxy metabolite of carbendazim is neither 
teratogenic in the rat nor cytotoxic in vitro (Styles and Garner,
197*0. It is not believed that carbendazim can be regenerated from any
of its metabolites. Therefore, teratogenicity is due to carbendazim 
alone (i.e. SPTM =1).
A study of the teratogenicity of febantel and its metabolites in 
the rat (Delatour et al., 1982b) demonstrated that the SPTM = 4
(febantel plus three metabolites, including fenbendazole and 
oxfendazole). In the case of a pro-drug of oxfendazole (Hennessy et 
al., 1983) and the compound R34803 (Michiels et al., 1982), a similar 
SPTM was observed.
The ADI of drug residues found in edible tissues is calculated 
from the NOAEL in the most sensitive species, using metabolites
included in the SPTM. The uncertainty (safety) factor chosen for
biological effects such as teratogenicity, is 1,000 (U.S. EPA, 1980).
Therefore, for carbendazim, a NOAEL of 9.5 mg/kg in the rat corresponds 
to an ADI of 570 jig/day in humans (60 kg body weight), a value which is 
sensibly low considering results from genotoxicity studies (NOAEL = 
5 mg/kg, uncertainty factor = 100).
Mutagenic activity of benzimidazoles has been demonstrated mainly 
in bacteria and fungi. Only carbendazim has been shown to possess 
mutagenic activity in mammals (using the mammalian spot test and the 
micronucleus test). The dose-effect in the micronucleus test indicated 
that carbendazim was genotoxic in the mouse at an oral dose of 
100 mg/kg, but, at a dose of 50 mg/kg, carbendazim was not genotoxic 
(Seiler, 1975b).
WITHDRAWAL TIMES
Withdrawal times may be calculated from the depletion of total 
residues, depletion of extractable metabolites, or depletion of 
potentially toxic metabolites. More correctly, withdrawal times should 
be calculated on the basis that the sample contains less than the 
acceptable daily intake. In the past, arbitrary figures were chosen in 
setting withdrawal times, partly because analytical methods were 
insensitive, and partly because of difficulties in assessing the exact 
nature of residues. In recent years, methods have become much more 
sensitive and specific, with residues being detectable at much lower 
concentrations and for much longer periods of time.
CHAPTER 3 
MATERIALS AND METHODS
The analysis of benzimidazole anthelmintics is difficult, due to 
the fact that they are poorly soluble in water (Ngomuo 1983) 
(Table 3.1) and have limited solubility in only a few organic 
solvents.
High Performance Liquid Chromatographic techniques require that 
the injected sample is uncontaminated (i.e. free of lipids, proteins, 
etc). Thus, development of a method for the determination of 
benzimidazoles and their metabolites in tissues posed a great problem 
as regards co-extracted lipids. This problem of co-extracted lipids is 
normally overcome in the analysis of other drugs by one or a 
combination of the following methods:
(1) Precipitation techniques using Sodium Tungstate, Zinc Sulphate, 
or other salts.
(2) Solvent/Solvent partitioning using two solvents, one of which is 
miscible with water.
(3) Column chromatographic clean-up.
(4) Acid/Base partitioning.
Considerable effort was made to utilise these techniques for 
benzimidazoles and their metabolites, but none of these was found 
useful since for the following reasons:
(1) In precipitation methods, contaminating lipids were precipitated 
out, but the supernatant, although clear, contained only about 
ten per cent of the total drug added.
(2) Petroleum ether/acetonitrile partition chromatography serves a 
dual role as both an extraction and a clean-up procedure. By 
using a polar and a non-polar solvent together, the fat is 
dissolved in the non-polar solvent, leaving the compounds of 
interest in the more polar solvent. The more polar solvent is 
then extracted using the non-polar solvent which is then 
evaporated to a small volume for transfer to a Florisil column.
This technique is used in many residue analyses (e.g. for 
organochlorine compounds), but benzimidazoles are poorly soluble 
in petroleum ether and acetonitrile, therefore, separation from 
lipids was not possible by this technique.
(3) In column chromatography using Florisil, sulphide and sulphoxide 
benzimidazole eluates contained large quantities of lipid, using 
a range of organic solvents and methods such as are commonly 
used for pesticide residue analysis.
(4) Normally, basic substances such as benzimidazoles and their 
metabolites, can be extracted from an aqueous alkaline solution 
into organic solvents and can then be re-extracted free from 
neutral lipids by extraction of the organic solvent with acid.
It was established that the parent benzimidazoles and their 
metabolites are only very poorly extractable by acids from
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organic solvents (less than ten per cent recovery). Therefore, 
the possibility of clean-up of tissue residue extracts using 
back extraction into aqueous solvents was not possible.
Although benzimidazoles and their metabolites are poorly 
extracted into acid from organic solvents, it was discovered that they 
are stable even in strong acids (i.e. 3N HC1).
This property of the benzimidazoles was utilised in developing a 
suitable method which was found to give good recoveries of all the 
benzimidazoles studied and their toxicologically important metabolites 
(Tables 3.2-3.9).
METHOD FOR THE DETERMINATION OF BENZIMIDAZOLE RESIDUES IN LIVER, 
MUSCLE AND KIDNEY
Reagents:
All aqueous solutions were prepared using permanganate distilled 
water.
Diethyl ether - washed with ferrous sulphate and stabilised with
(Analar) pyrogallol before use.








Frozen samples were thawed overnight in a refrigerator.
(1) The tissue was finely chopped with a scalpel and about 2.5g was 
weighed accurately and added to a 50ml ground glass stoppered 
tube.
(2) 5ml of 3N HC1 were added and the tube stoppered and placed in a 
boiling water bath for 60 minutes.
(3) The tube was removed from the boiling water bath and cooled to 
room temperature.
(4) The tube was vortexed and, while being vortexed, 1.2g of sodium 
carbonate were slowly added. This brought the sample to a pH of 
approximately 9.
(5) 40ml of diethyl ether were added to the tube and the tube shaken 
on a slow rotary mixer for 15 minutes.
(6) 30ml of the diethyl ether were removed into a 50ml thin-walled
tube and evaporated to dryness using a dry bath at 50°C with
air.
(7) When the tube was dry 2ml of 1N HC1 were added and the tube
vortexed and filtered through Whatman No.1 paper pre-wetted with 
1N HC1. The tube was vortexed with a further 4 x 2ml of 1N HC1, 
again filtering each 2ml fraction.
(8) After filtering, the filtrate was vortexed and 0.8g of sodium
carbonate slowly added. This brought the sample to a pH of
approximately 9.
(9) 40ml of diethyl ether were added to the filtrate and the tube
was shaken on a slow rotary mixer for 15 minutes.
(10) 30ml of the diethyl ether were removed into a 50ml thin-walled
tube and evaporated to approximately 4ml using a dry bath at
50° C with air.
The remaining 4ml were transferred to a 10ml conical tube.
The 50ml tube was washed with 2 x 2ml of diethyl ether and the
washings were added to the 10ml conical tube.
The washings were evaporated to dryness, then the side of the
10ml conical tube was washed with approximately 1ml of diethyl 




(14) The sample was resuspended in 75 microliters (ul) of methanol, 
placed in a sonic bath for 2 minutes and 5ul were injected onto 
the H.P.L.C. column.
Recoveries were estimated using blank tissue samples spiked with 
working standards which were prepared in methanol.
Spiking was carried out immediately after addition of the tissue 
to the tube, i.e. before the 3N HC1 was added.
Parent compounds were measured along with their respective 
sulphoxide and sulphone metabolites.
The limit of detection for these compounds varied according to 
column performance, although a limit of 0.05 micrograms (ug) per gram 
could consistently be achieved.
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
Unfortunately, benzimidazoles and their metabolites cannot be 
measured using a single chromatographic system (Marriner and Bogan, 
1980).
(1) With a mobile phase of methanol:ammonium carbonate the following 
were easily measured:
albendazole, fenbendazole, thiabendazole and 5- hydroxy
-thiabendazole. The sulphoxide and sulphone metabolites have 
identical retention times.
(2) With a mobile phase of methanol:perchloric acid the following 
were measured:
albendazole sulphoxide, albendazole sulphone, oxfendazole and 
oxfendazole sulphone.
Therefore, two chromatographic systems have to be used to measure the 
parent benzimidazoles and their important’metabolites.
Pumps : Gilson Model 302
Detectors : Cecil CE 2012 variable wavelength
U.V. spectrophotometer
Columns : 100mm x 5mm i.d. (Shandon Southern)
Packing : ODS-Hypersil. 5 micron
Wavelengths : 292nm
Absorbances : 0.05 a.u.f.s.
Solvents and Flow Rates:
(1) Methanol: Ammonium Carbonate (0.05M) 70:30 (1 ml/rain)
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(2) Methanol: Water 65:35 + 1pl of perchloric acid (0.7 ml/min)
(1.1% w/v) per ml of solvent
(3) Methanol: Ammonium Carbonate (0.05M) 40:60 (1 ml/min)
Retention Times : varied slightly and are therefore only approximate.
Retention Time Solvent
Albendazole 4 min 1
Albendazole Sulphoxide 4 min 2
Albendazole Sulphone 2.5 min 2
Retention Time Solvent
Fenbendazole 5 min 1
Oxfendazole 4.5 min 2
Oxfendazole Sulphone 2.5 min 2
Retention Time Solvent
Thiabendazole 8 min 3
5-hydroxythiabendazole 3 min 3
Although thiabendazole and 5-hydroxythiabendazole were measured using 
a mobile phase of methanol:ammonium carbonate; under the conditions 
used to measure albendazole and fenbendazole, their retention times 
were too short and therefore the proportions of methanol and ammonium 
carbonate had to be altered to allow their detection. Hence, the 
requirement for a third mobile phase.
36
It was found that a shortened version of the tissue method could
be applied to milk samples giving good recoveries for all
benzimidazoles used and their principal metabolites 
(Tables 3.10-3.12).
METHOD FOR THE DETERMINATION OF BENZIMIDAZOLE RESIDUES IN MILK 
Reagents:
All aqueous solutions were prepared using permanganate distilled 
water.
Diethyl ether - washed with ferrous sulphate and stabilised .
(Analar) with pyrogallol before use.









(1) 5ml of milk were added to a 50ml thin-walled tube.
(2) 5ml of 1N HC1 were added and the tube vortexed.
(3) The sample was filtered through Whatman No.1 paper pre-wetted 
with 1N HC1 into a 50ml ground glass stoppered tube. The tube 
was vortexed with a further 5ml of 1N HC1 (2+2+1ml) and the 
washings filtered.
(4) The filtrate was vortexed and 0.8g of sodium carbonate added 
slowly. This brought the sample to a pH of approximately 9.
(5) 40ml of diethyl ether were added and the tube was shaken on a 
slow rotary mixer for 15 minutes.
(6) 30ml of diethyl ether were then removed into a 50ml thin-walled 
tube and evaporated to approximately 4ml.
(7) The remaining 4ml were transferred to a 10ml conical tube.
(8) The 50ml tube was washed with 2 x 2ml of diethyl ether and the
washings were added to the 10ml conical tube.
(9) The diethyl ether was evaporated to dryness and the side of the 
tube was washed with 1ml of diethyl ether and again evaporated 
to dryness.
(10) The sample was resupsended in 75ul of methanol, placed in a
sonic bath for 2 minutes and 5ul were injected onto the
H.P.L.C. column.
Recoveries were estimated by the same method as that used for tissues.
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This method was also applied to fat-free milk samples which were
prepared in the following way:-
(1) To 10ml of milk were added 200pl of a commercial preparation of 
rennin (Rennet).
(2) The milk was incubated in a water bath at 40°C for one hour.
(3) The milk was centrifuged at 3000 rpm for 15 minutes and the 
supernatant decanted off into a tube for extraction by the milk 
method previously described.
The limit of detection for benzimidazoles and their metabolites 
in milk and fat-free milk varied, again due to column 
performance, although a limit of 0.05jig per ml could 
consistently be achieved.
The analysis of benzimidazoles and their metabolites in plasma 
and ruminal fluid was straightforward since a method was already 
available (Bogan and Marriner, 1980) and is as follows:-
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METHOD FOR THE DETERMINATION OF BENZIMIDAZOLES AND THEIR METABOLITES
IN PLASMA AND RUMINAL FLUID
(1) To 4ml of plasma or ruminal fluid in a 50ml stoppered tube were 
added 0.4g of sodium chloride, 0.4ml of ammonium hydroxide 
(0.1N) and 20ml of diethyl ether.
(2) The tube was shaken for 15 minutes on a slow rotary mixer.
(3) 15ml of the diethyl ether were removed into a 50ml thin-walled
tube and a further 20ml of diethyl ether was added to the first
tube, which was shaken for a further 15 minutes.
(4) 20ml of diethyl ether was removed and combined with the initial 
15ml of diethyl ether.
(5) The diethyl ether was evaporated to approximately 4ml using a 
dry bath at 50°C with air.
(6) The remaining 4ml was transferred to a 10ml conical tube.
(7) The 50ml tube was washed with 2 x 2ml of diethyl ether and the 
washings added to the 10ml conical tube.
(8) The diethyl ether was then evaporated to dryness and the side of 
the 10ml conical tube washed with approximately 1ml of diethyl 
ether and again evaporated to dryness.
(9) The sample was resuspended in 100pl of methanol, placed on a 
sonic bath for 2 minutes and 5^1 were injected onto the
H.P.L.C. column.
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TABLE 3.1 The solubilities of albendazole, fenbendazole,
oxfendazole and thiabendazole in phosphate buffer











TABLE 3.2 Estimation of albendazole (ABZ) following spiking of
liver, muscle and kidney
LIVER
ABZ ABZ MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.62 1.64 + 0.02 1.2 0.66
2.5 1.65
1.25 0.82 0.81 + 0.01 1.2 0.65
1.25 0.80
0.5 0.31 0.32 + 0.01 3.1 0.64
0.5 0.33
MUSCLE
ABZ ABZ MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.55 1.56 + 0.01 0.6 0.62
2.5 1.57
1.25 0.77 0.76 + 0.01 0.6 0.61
1.25 0.76
0.5 0.28 0.28 + 0.01 1.8 0.56
0.5 0.29
KIDNEY
ABZ ABZ MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.63 1.62+0.01 0.6 0.65
2.5 1.61
1.25 0.81 0.80 + 0.01 1.2 0.64
1.25 0.79
0.5 0.32 0.31 + 0.01 3.2 0.62
0.5 0.30
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TABLE 3*3 Estimation of albendazole sulphoxide (ABSX)
following spiking of liver, muscle and kidney
LIVER
ABSX ABSX MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED'(jig) S.E.M. % ASSAYED TO ADDED
2.5 1.-47 1.46 + 0.01 0.7 0.58
2.5 1.45
1.25 0.70 0.70 + 0.01 0.7 0.56
1.25 0.71
0.5 0.28 0.27 + 0.01 3.7 0.54
0.5 0.26
MUSCLE
ABSX ABSX, MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.35 1.34 + 0.02 1.1 0.54
2.5 '1.32
1.25 0.67 0.66 + 0.02 2.3 0.53
1.25 0.64
0.5 0.28 0.28 + 0.01 1.8 0.56
0.5 0.29
KIDNEY
ABSX ABSX MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.44 1.43 + 0.01 0.7 0.57
2.5 1.42






0.26 + 0.01 1.9 0.52
TABLE 3.4 Estimation of albendazole sulphone (ABSO)
following spiking of liver, muscle and kidney
LIVER
ABSO ABSO MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.81 1.80 + 0.01 0.6 0.72
2.5 1.79
1.25 0.89 0.90 + 0.01 1.1 0.72
1.25 0.91
0.5 0.36 0.36 + 0.01 1.4 0.72
0.5 0.37 •
MUSCLE
ABSO ABSO MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.75 1.76 + 0.01 0.6 0.70
2.5 1.77
1.25 0.86 0.85 + 0.01 1.2 0.68
1.25 0.84
0.5 0.34 0.34 + 0.01 1.5 0.68
0.5 0.35
KIDNEY
ABSO ABSO MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.80 1.78 + 0.02 1.1 0.71
2.5 1.76
1.25 0.85 0.86 + 0.01 0.6 0.69
1.25 0.86
0.5 0.34 0.33 + 0.01 3.0 0.66
0.5 0.32
TABLE 3*5 Estimation of fenbendazole (FBZ)
following spiking of liver, muscle and kidney
LIVER
FBZ FBZ MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.71 1.69 + 0.02 1.2 0.68
2.5 1.67
1.25 0.87 0.88 + 0.01 0.6 0.70
1.25 0.88
0.5 0.33 0.34 + 0.02 4.4 0.68
0.5 0.36
MUSCLE
FBZ FBZ MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.65 1.65 + 0.02 0.9 0.66
2.5 1.62
1.25 0.83 0.84 + 0.01 1.2 0.67
1.25 0.85
0.5 0.29 0.30 + 0.02 5.0 0.60
0.5 0.32
KIDNEY
FBZ FBZ MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.69 1.66 + 0.02 1.5 0.66
2.5 1.64
1.25 0.85 0.86 + 0.01 1.2 0.69
1.25 0.87
0.5 0.31 0.30 + 0.01 3.3 0.60
0.5 0.29
TABLE 3.6 Estimation of oxfendazole (OFZ)
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TABLE 3.7 Estimation of oxfendazole (OFZ.SO)
following spiking of liver, muscle and kidney
LIVER
OFZ.SO. OFZ.SO. MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.91 1.89 + 0.02 1.1 0.76
2.5 1.87
1.25 0.96 0.94 + 0.02 1.6 0.75
1.25 0.93
0.5 0.36 0.38+0.02 3.9 0.76
0.5 0.39
MUSCLE
OFZ.SO. OFZ.SO. MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.87 1.86 + 0.02 0.8 0.74
2.5 1.84
1.25 0.90 0.91 +' 0.01 1.1 0.73
1.25 0.92
0.5 0.33 0.35 + 0.02 5.7 0.70
0.5 0.37
KIDNEY
OFZ.SO. OFZ.SO. MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.89 1.86 + 0.02 1.3 0.74
2.5 1.84
1.25 0.92 0.91 + 0.01 1.1 0.73
1.25 0.90
0.5 0.37 0.36+0.01 1.4 0.72
0.5 0.36
TABLE 3.8 Estimation of thiabendazole (TBZ)
following spiking of liver, muscle and kidney
LIVER
TBZ TBZ MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.45 1.47 + 0.02 1.4 0.59
2.5 1.49
1.25 0.70 0.72 + 0.02 2.8 0.58
1.25 0.74
0.5 0.31 0.30 + 0.01 3.3 0.60
0.5 0.29
MUSCLE
TBZ TBZ MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.41 1.42 + 0.01 0.7 0.57
2.5 1.43
1.25 0.65 0.67 + 0.02 3.0 0.54
1.25 0.69
0.5 0.28 0.29 + 0.01 3.4 0.58
0.5 0.30
KIDNEY
TBZ TBZ MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.48 1.46 + 0.02 1.4 0.58
2.5 1.44
1.25 0.71 0.70 + 0.01 1.4 0.56
1.25 0.69
0.5 0.33 0.32 + 0.01 3.1 0.64
0.5 0.31
TABLE 3.9 Estimation of 5-hydroxythiabendazole (5-OH TBZ)
following spiking of liver, muscle and kidney
LIVER
5-OH TBZ 5-0H TBZ MEAN + S.E.M. RATIO OF
ADDED (jig) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.55 1.52 + 0.02 1.6 0.61
2.5 1.50
1.25 0.76 0.75 + 0.01 1.3 0.60
1.25 0.74
0.5 0.31 0.29 + 0.02 6.9 0.58
0.5 0.27 *
MUSCLE
5-OH TBZ 5-OH TBZ MEAN + S.E.M. RATIO OF
ADDED (jig) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.49 1.50 + 0.01 0.7 0.60
2.5 1.51
1.25 0.74 0.75 + 0.01 1.3 0.60
1.25 0.76
0.5 0.28 0.26 + 0.02 5.8 0.52
0.5 0.25
KIDNEY
5-OH TBZ 5-OH TBZ MEAN + S.E.M. RATIO OF
ADDED (jig) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
2.5 1.53 1.52 +0.01 0.7 0.61
2.5 1.51
1.25 0.77 0.76 + 0.01 1.3 0.61
1.25 0.75
0.5 0.33 0.31 + 0.02 6.4 0.62
0.5 0.29
TABLE 3.10 Estimations of albendazole (ABZ), albendazole
sulphoxide (ABSX) and albendazole sulphone (ABSO) 
following spiking of cows’ milk
ABZ ABZ MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
5.0 3.96 3.92 + 0.04 0.9 0.78
5.0 3.89
2.5 1.87 1.89 + 0.02 1.1 0.76
2.5 1.91
0.5 0.37 0.36 + 0.01 2.8 0.72
0.5 0.35
ABSX ABSX MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
5.0 3.26 3.30 + 0.04 1.1 0.66
5.0 3.33
2.5 1.59 1.62 + 0.02 1.5 0.65
2.5 1.64
0.5 0.33 0.31 + 0.02 6.4 0.62
0.5 0.29
ABSO ABSO MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
5.0 4.01 3.96 + 0.04 1.1 0.79
5.0 3.92
2.5 1.97 2.00 + 0.02 1.2 0.80
2.5 2.02
0.5 0.39 0.38 + 0.02 3.9 0.76
0.5 0.36
TABLE 3*11 Estimations of fenbendazole (FBZ), oxfendazole (OFZ)
and oxfendazole sulphone (OFZ.SO) following spiking
of cows1 milk
FBZ FBZ MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
5.0 3.81 3.79 + 0.02 0.5 0.76
5.0 3.77
2.5 1.86 1.90 +0.04 1.8 0.76
2.5 1.93
0.5 0.37 0.38 + 0.01 1.3 0.76
0.5 0.38
OFZ OFZ MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (jig) S.E.M. % ASSAYED TO ADDED
5.0 2.69 2.67 + 0.02 0.7 0.53
5.0 2.65
2.5 1.32 1.34 + 0.02 1.5 0.54
2.5 1.36
0.5 0.28 0.27 + 0.01 3.7 0.54
0.5 0.26
OFZ.SO. OFZ.SO. MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
5.0 3.93 3.95 + 0.02 0.5 0.79
5.0 3.97






0.38 + 0.02 3.9 0.76
TABLE 3.12 Estimations of thiabendazole (TBZ) and
5-hydroxythiabendazole (5-OH TBZ)
following spiking of cows* milk
TBZ TBZ MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
5.0 3.54 3.58 + 0.04 1.3 0.72
5.0 3.63
2.5 1.80 1.76 + 0.04 2.0 0.70
2.5 1.73
0.5 0.37 0.35 + 0.02 5*7 0.70
0.5 0.33
5-OH TBZ 5-OH TBZ MEAN + S.E.M. RATIO OF
ADDED (pg) MEASURED (pg) S.E.M. % ASSAYED TO ADDED
5.0 3.88 3.90 + 0.02 0.6 ■ 0.78
5.0 3.93
2.5 1.87 1.88 + 0.01 0.5 0.75
2.5 1.89
0.5 0.36 0.37 + 0.01 2.7 0.74
0.5 0.38
The methods described have been shown to be very suitable for 
the determination of benzimidazoles and their toxicologically 
important metabolites. Recoveries of all the compounds were generally 
very similar at all concentrations measured and for all tissues. As 
for the limits of detection, they were considered to be when the peak 
heights of the analytes were twice the base-line variation.
At the outset of this study it was not our intention to 
determine kidney residues of benzimidazoles and their metabolites, 
however, we were provided with kidney samples by Robert Young and 
Company and found that our methods were applicable to this tissue. For 
this reason, kidney samples were not included in all of the studies.
ANIMALS
All sheep and cattle used in the residue studies were of mixed breed 
and sex. The animals were of different ages, but all were adult.
FEEDING
All animals were maintained on a diet of hay with a small amount of 
concentrates and water ad libitum, throughout the duration of the 
residue trials.
DOSING
All drugs were given orally by drench.
SAMPLING
Blood samples were taken by jugular venepuncture into 10ml heparinised 
syringes (Monovettes). The blood was centrifuged immediately at 3000 x
o
g for 15 minutes, the plasma removed and stored at -20 C until 
assayed.
Rumen fluid samples were obtained via rumen cannulae which had been 
inserted at least one month before the study had begun. The fluid was 
centrifuged immediately at 3000 x g for 10 minutes, the supernatant
removed and stored at -20°C until assayed.
TISSUE SAMPLES
Liver, muscle and kidney samples were taken at slaughter and stored
immediately at -20°C until assayed. In all of the studies carried out, 
liver and kidney samples were aliquots taken from large portions of 
chopped tissue, to give a representative sample of the whole organ. 
Muscle tissue was consistently taken from the thigh of the animal.
CHAPTER 4
STUDIES WITH ALBENDAZOLE AND ALBENDAZOLE SULPHOXIDE
IN SHEEP
INTRODUCTION
Albendazole (5-(propylthio)-1H-benzimidazol-2-yl-carbamate) is a 
potent member of the benzimidazole group of anthelmintics with broad 
spectrum activity against gastro-intestinal roundworms including 
inhibited larval stages, tapeworms, liver flukes and lungworms in many 
species (Theodorides et al., 1976). It is the first broad spectrum
anthelmintic to have useful efficacy at low dose levels against all 
major economically important helminth parasites infecting domestic 
animals. In sheep and cattle, it is widely used in the control of 
gastro-intestinal nematodes and tapeworms, lungworms and liver flukes 
(Knight and Colglazier, 1977).
The metabolism of albendazole has been extensively studied 
(Gyurik et al., 1981), with nine metabolites being identified in the 
urine of cattle, sheep, rats and mice which had been given 
140-labelled albendazole orally (Figure 4.1). Albendazole is 
metabolised by oxidation at the sulphur atom, by aliphatic and 
aromatic hydroxylation, methylation at both nitrogen and sulphur, and 
carbamate hydrolysis. Unchanged albendazole was present in only minor 
amounts in urine. The percentage of each metabolite was measured after 
samples of urine from each species were extracted with ethyl acetate 
and the metabolites separated by thin-layer chromatography 
(Table 4.1).
The most important metabolic reactions leading to the observed 
urine metabolites were oxidation at alkyl and sulphur, and carbamate 
hydrolysis. All the observed urine metabolites were sulphoxides or 
sulphones. The oxidation of alkyl and aryl sulphides to more polar
eft
sulphoxides and sulphones is commonly observed and facilitates urinary 
excretion (Duggan et al., 1977).
In all species studied, metabolite C (Figure 4.1) was found in 
higher concentrations than any of the other metabolites isolated, with 
the exception of mouse urine in which metabolite G was most abundant. 
In cattle and sheep, metabolite I was found to be a major urinary 
metabolite. Metabolite E was found in sheep urine in high 
concentrations, but in cattle urine, was found in lower concentrations 
than in sheep urine. Metabolite A has been identified in the plasma of 
cattle and sheep (Marriner and Bogan, 1980) but is not a major urinary 
metabolite in these species. Metabolite A is chemically identical to 
albendazole sulphone and metabolite C is chemically identical to 
albendazole sulphoxide. Albendazole 2-amino sulphone (Metabolite I), 
although a major urinary metabolite in cattle and sheep, is not a 
major metabolite in the plasma of these species. Albendazole 
sulphoxide and albendazole sulphone are the major metabolites found in 
the plasma of cattle and sheep after the administration of albendazole 
(Marriner and Bogan, 1980).
The facile metabolic interconversion of alkyl and aryl sulphides 
and sulphoxides has been reported (Duggan et al., 1980). This has been 
confirmed for albendazole and albendazole sulphoxide (Douch and 
Buchanan, 1979). When rats were dosed with albendazole sulphone, no 
sulphoxide metabolites were detected in urine. The metabolic oxidation 
of sulphoxide to sulphone appears to be irreversible (Kexel and 
Schmidt, 1972).
c;o
When administered orally, albendazole and albendazole sulphoxide 
have similar anthelmintic and embryotoxic activities. However, all of 
the other identified metabolites of albendazole have little 
anthelmintic activity and do not appear to be teratogenic in the rat 














































TABLE 4.1 Percentage distribution of radioactivity in the
thin-layer chromatographic zones corresponding to 
various metabolites in extracts of urine from
14animals treated orally with C-albendazole. 
(Gyurik et al.t 1981)
METABOLITE CATTLE SHEEP RAT MOUSE
%
ALBENDAZOLE 0.1 1.0 1.9 0.5
A (Albendazole sulphone) 5.8 3.4 5.5 1.3
B 6.3 8.9 0.0 0.0
C (Albendazole sulphoxide) 22.9 24.3 26.6 24.2
E 7.5 22.5 14.0 21.6
F 2.8 4.5 0.0 5.7
G 9.2 4.3 24.2 29.9
H 6.6 5.1 0.0 0.0
I (Albendazole 2-aminosulphone) 20.9 20.2 14.8 3.7
J 4.4 1.6 0.5 4.7
TOTAL RECOVERED 86.5 95.6 87.6 91.6
TOXICITY OF ALBENDAZOLE
The toxicity of albendazole and its metabolites has been 
extensively studied (Martin, 1980; Grannec, 1980; Delatour et al., 
1981; Delhoste, 1983).
Delatour et al., (1981) compared the relay embryotoxicity of 
albendazole with the embryotoxicity of its individual metabolites. In 
these studies, cattle were given albendazole at an experimental dosage 
of 20 mg/kg body weight. The animals were slaughtered at 24, 48 and 
96 hours after dosing, their livers removed immediately after 
slaughter and frozen. The frozen livers were freeze-dried and the 
freeze-dried livers fed to gestating rats. It was found that rats fed 
liver from albendazole treated cattle did not differ significantly 
from rats fed liver from untreated control cattle with respect to 
observed embryotoxicity (embryolethality, foetotoxicity,
terato-genicity). Scott and Dicuollo (1980) have shown that in rats 
treated with liver obtained from calves which had been dosed with 
albendazole, the bioavailability of total residues was very low 
(i.e. residues were very poorly absorbed from the rat 
gastro-intestinal tract). These results suggest that relay toxicity 
does not occur with albendazole.
Pregnant rats were also treated with albendazole (Delatour et 
al., 1981) or one of its various metabolites (Figure 4.1) from the
eighth to the fifteenth day of gestation, each day at the same time. 
Albendazole was found to be embryotoxic in the dose range of
6.62 mg/kg to 13.25 mg/kg but, of all the known metabolites of
albendazole, including all the major urinary metabolites, only
metabolite C (albendazole sulphoxide) was found to be embryotoxic. In
fact, albendazole sulphoxide reproduces exactly the toxic effects of 
the parent compound (Delatour et al., 1981).
When SKF 525-A (an inhibitor of microsomal oxidation) and
albendazole are administered concurrently, the embryotoxic effects of 
albendazole are eliminated (Delatour et al., 1984). This is probably 
due to an inhibitory effect of SKF 525-A upon gastro-intestinal 
absorption of albendazole, rather than an inhibition of enzymatic 
S-oxidation (Delatour et al.t 1984).
From a toxicological point of view, it is clear from these 
experiments that in any residue studies involving albendazole, it is 
most important that the parent albendazole and albendazole sulphoxide 
should be measured, since none of the other metabolites of albendazole 
have been found to be toxic.
In the following experiments with albendazole and albendazole 
sulphoxide, only the parent sulphide, and the sulphoxide and sulphone 
metabolites were measured (Figure 4.2). The reason for measuring 
albendazole sulphone was that, although it is not toxicologically 
important, it is a major plasma metabolite of albendazole (Marriner 
and Bogan, 1980) and persists longer in plasma than albendazole 
sulphoxide. Also, under the chromatographic conditions used to measure 
albendazole sulphoxide, albendazole sulphone is easily measured.
All
FIGURE 4.2 Albendazole and its important metabolites.
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TABLE 4. The meat and milk withholding times 
for albendazole in sheep and cattle 
in the United Kingdom.








These studies involved the administration of albendazole or 
albendazole sulphoxide to sheep, both at a dose rate of 5 mg/kg. All 
treatments were by oral drench, and the animals were slaughtered at 1, 
3, 5 and 8 days post-treatment. For the sheep treated with
albendazole, samples of liver and muscle were taken at slaughter and
stored immediately at -20°C until assayed (as described in Chapter 3). 
They were assayed in duplicate (Table 4.3). Blood samples were also 
taken at intervals throughout the course of the experiment to assess 
tissue/plasma ratios; plasma was removed after centrifugation and
stored at -20°C until assayed (Table 4.3). For the sheep treated with 
albandazole sulphoxide, samples of liver, muscle and kidney were taken 
at slaughter and assayed as previously described (Table 4.4).
A third experiment was carried out in which two sheep with 
permanent rumen cannulae were given albendazole sulphoxide as an oral 
drench, at a dose rate of 5 mg/kg. Samples of ruminal fluid (10 ml) 
were taken before and at 2, 4, 8, 12, 24, 36, 48, 72 and 96 hours
after treatment. The samples were centrifuged, the supernatant removed
and stored immediately at -20°C until assayed (as described in 
Chapter 3). All ruminal fluid samples were assayed for albendazole 
sulphoxide and albendazole (Table 4.5).
After albendazole treatment (Table 4.3), albendazole itself was 
found in liver in high concentrations at one day post-treatment (at a 
concentration of 11.80 pg/g). This was surprising since albendazole 
itself was detected in plasma only at very low concentrations 
(0.02 pg/ml) after albendazole treatment at a dose rate of 10 mg/kg 
(Marriner and Bogan, 1980).
At three days post-treatment, albendazole was still detectable 
in liver (although only a trace amount was present), but, at five days 
post-treatment, concentrations had fallen below a detectable level.
Albendazole sulphoxide was detectable in liver at one day 
post-treatment (at a concentration of 1.65 pg/g), but, highest 
concentrations were found at three days post-treatment (3.28 pg/g). At 
five days post-treatment, albendazole sulphoxide was no longer 
detectable in liver.
Albendazole sulphone was also detectable in liver at one day 
post-treatment (at a concentration of 1.94 pg/g), but, at three days 
post-treatment, concentrations had fallen below a detectable level.
In muscle, albendazole was detectable at one day post-treatment 
(at a concentration of 0.68 pg/g), although in a much lower 
concentration than was found in liver at the same time. At three days 
post-treatment, albendazole was no longer detectable in muscle.
Albendazole sulphoxide was detectable in muscle at one day
post-treatment (at a concentration of 0.68 pg/g), but, at three days 
post-treatment, concentrations had fallen below a detectable level.
Albendazole sulphone was also detectable in muscle at one day 
post-treatment (at a concentration of 0.28 pg/g), but, at three days 
post-treatment, concentrations had fallen below a detectable level.
In plasma, albendazole itself was not detectable at any time 
after treatment (Table 4.6).
Albendazole sulphoxide was detectable in plasma, highest 
concentrations being found at one day post-treatment (1.57 pg/ml). At 
three days post-treatment, albendazole sulphoxide was still detectable 
(at a concentration of 0.04 pg/ml), but, at five days post-treatment, 
concentrations had fallen below a detectable level.
Albendazole sulphone was also detectable in plasma, highest 
concentrations being found at one day post-treatment (0.69 pg/ml). At 
three days post-treatment, albendazole sulphone was still detectable 
(at a concentration of 0.05 pg/ml), but, at five days post-treatment, 
concentrations had fallen below a detectable level (< 0.02pg/ml).
TABLE 4.3 Liver, muscle and plasma residues of albendazole 
and its metabolites in sheep.
LIVER
Residues (pg/g wet wt)








65 5mg/kg 3 TRACE 3.28 N.D.
97 5mg/kg 5 N.D. N.D. N.D.
4 5mg/kg 8 N.D. N.D. N.D.
110 5mg/kg
MUSCLE
1 0.68 0.68 0.28
65 5mg/kg 3 N.D. N.D. N.D.
97 5mg/kg 5 N.D. N.D. N.D.






65 5mg/kg 3 N.D. 0.04 0.05
97 5mg/kg 5 N.D. N.D. N.D.
4 5mg/kg 8 N.D. N.D. N.D.
ABZ = albendazole * = Mean values of two determinations
ABSX = albandazole sulphoxide
ABSO = albendazole sulphone N.D. = Not detected
(< 0.05pg/g or pg/ml)
After albendazole sulphoxide treatment (Table 4.4), albendazole
sulphoxide was detectable in liver at one day post-treatment (at a 
mean concentration of 3.36 pg/g). At three days post-treatment, it was 
still detectable (at a mean concentration of 0.74 pg/g), but, at five
days post-treatment, concentrations had fallen below a detectable
level.
Albendazole sulphone was also detectable in liver at one day
post-treatment (at a mean concentration of 2.94 pg/g). It was still 
detectable at three days post-treatment (although only a trace amount 
was present), but, at five days post-treatment, concentrations had 
fallen below a detectable level.
Surprisingly, albendazole was detectable in liver in high
concentrations at one day post-treatment (a mean concentration of 
14.21 pg/g), but, at three days post-treatment, concentrations had
fallen below a detectable level.
In muscle, albendazole sulphoxide was detectble at one day 
post-treatment (at a mean concentration of 1.87 pg/g), but, at three 
days post-treatment, concentrations had fallen below a detectable
level.
Albendazole sulphone was also detectable in muscle at one day
post-treatment (at a mean concentration of 1.07 pg/g)» but, at three 
days post-treatment, concentrations had fallen below a detectable
level.
Albendazole was not detectable in muscle at any time after 
treatment.
In kidney, albendazole sulphoxide was detectable at one day 
post-treatment (at a mean concentration of 6.84 pg/g), but, at three 
days post-treatment, concentrations had fallen below a detectable 
level.
Albendazole sulphone was also detectable in kidney at one day 
post-treatment (at a mean concentration of 2.14 pg/g), but, at three 
days post-treatment, concentrations had fallen below a detectable 
level.
Again, surprisingly, albendazole was detectable in kidney at one 
day post-treatment (at a mean concentration of 4.20 pg/g), but, at 
three days post-treatment, concentrations had fallen below a 
detectable level.
TABLE 4.4 Liver, muscle and kidney residues of albendazole 
sulphoxide and its metabolites in sheep.
LIVER
Residues (pg/g wet wt)
Animal No Dose Days after Treatment ABZ ABSX ABSO
583 5mg/kg 1 18.61 1.92 2.80
586 5mg/kg 1 9.82 4.81 3.09
MG 5mg/kg 3 N.D. 0.60 TRACE
MG 5mg/kg 3 N.D. 0.89 TRACE
693 5mg/kg 5 N.D. N.D. N.D.
CHE 5mg/kg 5 N.D. N.D. N.D.
692 5mg/kg 8 N.D. N.D. N.D.
SUF 5mg/kg 8 N.D. N.D. N.D.
MUSCLE
583 5mg/kg 1 N.D. 2.45 1.05
586 5mg/kg 1 N.D. 1.29 1.09
MG 5mg/kg 3 N.D. N.D. N.D.
MG 5mg/kg 3 N.D. N.D. N.D.
693 5mg/kg 5 N.D. N.D. N.D.
CHE 5mg/kg 5 N.D. N.D. N.D.
692 5mg/kg 8 N.D. N.D. N.D.
SUF 5mg/kg 8 N.D. N.D. N.D.
KIDNEY
583 5mg/kg 1 2.50 11.57 2.28
586 5mg/kg 1 5.90 2.12 2.00
MG 5mg/kg 3 N.D. N.D. N.D.
MG 5mg/kg 3 N.D. N.D. N.D.
693 5mg/kg 5 N.D. N.D. N.D.
CHE 5mg/kg 5 N.D. N.D. N.D.
692 5mg/kg 8 N.D. N.D. N.D.
SUF 5mg/kg 8 N.D. N.D. N.D.
ABZ = albendazole
ABSX = albendazole sulphoxide
ABSO = albendazole sulphone
N.D. = not detected (< 0.05 pg/g)
Marriner and Bogan (1980) reported that after the administration 
of albendazole to sheep, the parent sulphide was detectable only in 
very low concentrations in plasma. Only its metabolites albendazole 
sulphoxide and albendazole sulphone were detectable in plasma in high 
concentrations.
The surprise finding was that albendazole was detectable in high 
concentrations in liver after its administration to sheep. It was also 
detectable in liver after its administration to cattle, but to a 
lesser extent.
Even more surprising was the finding that albendazole was 
detectable in liver and kidney after the administration of albendazole 
sulphoxide to sheep. It was also detectable in liver and kidney after 
the administration of albendazole sulphoxide to cattle, but to a 
lesser extent.
This experiment using ruminal fluid was devised to determine if 
the conversion of albendazole sulphoxide to albendazole 
(i.e. reduction of albendazole sulphoxide) occurred in the rumen. If 
this was so, these unexpected results would not be so difficult to 
explain.
Albendazole was detectable in ruminal fluid (Table 4.5). Maximum 
concentrations were reached at four hours post-treatment in both sheep 
(a mean concentration of 1.11 pg/ml). At forty-eight hours
post-treatment, albendazole was still detectable in one of the sheep 
(at a concentration of 0.05 pg/ml), but, at seventy-two hours 
post-treatment, concentrations had fallen below a detectable level.
Albendazole sulphoxide was also detectable in ruminal fluid. 
Maximum concentrations were reached at four hours post-treatment in 
one of the sheep (a concentration of 1.71 pg/ml) and at eight hours 
post-treatment in the other sheep (a concentration of 0.34 pg/ml). At 
thirty-six hours post-treatment, albendazole sulphoxide was still 
detectable in both sheep (a mean concentration of 0.20 pg/ml), but, at 
forty-eight hours post-treatment, concentrations had fallen below a 
detectable level.
TABLE 4.5 Rumen fluid concentrations of albendazole sulphoxide 
and its metabolites in sheep
CONCENTRATION (ug/ml)
TIME(h) ALBENDAZOLE ALBENDAZOLE RATIO OF
SULPHOXIDE ABZ./ABSX.
0 0.00 0.00 A 0
0.00 0.00 B 0
2 1.04 0.88 A 1.18
0.36 0.22 B 1.64
4 1.75 1.71 A 1.02
0.48 0.31 B 1.55
8 1.25 0.66 A 1.89
0.36 0.34 B 1.06
12 0.73 0.44 A 1.66
0.30 0.12 B 2.50
24 0.45 0.22 A 2.04
0.18 0.14 B 1.28
36 0.21 0.32 A 0.66
0.06 0.09 B 0.67
48 0.05 N.D. A _
N.D. N.D. B -
72 N.D. N.D. A _
N.D. N.D. B -
96 N.D. N.D. A _
N.D. N.D. B -
N.D. = not detected A = sheep No.1 B = sheep
(< 0.05 jag/ml)
ABZ = albendazole
ABSX = albendazole sulphoxide
DISCUSSION
After the administration of albendazole or albendazole 
sulphoxide to sheep, residues were similar qualitatively and 
quantitatively.
With both treatments, the concentrations of liver residues were 
approximately five to ten times greater than the concentrations of 
muscle and plasma residues.
Tissue residues appear to follow the same pattern as plasma 
residues in that for both tissues and plasma, highest concentrations 
were reached at one day post-treatment and at five days 
post-treatment, concentrations had fallen below detectable levels.
High concentrations of the sulphide albendazole were found in 
liver after both treatments. This was indeed surprising since, after 
the administration of albendazole to sheep at a dose rate of 10 mg/kg 
(twice the dose used in these studies), albendazole was detectable 
only in very low concentrations in the plasma of two sheep (a mean
plasma of a third sheep (limit of detection 0.02 pg/ml) (Marriner and 
Bogan, 1980). With albendazole treatment, it was possible that 
unchanged albendazole was absorbed from the gut and via the hepatic 
portal system, travelled to the liver where it became bound. Delatour 
et al., (1983) found that albendazole binds to liver protein, although 
the extent and mechanism of binding are unknown. This may explain, in 
part, the presence of high concentrations of parent albendazole in the
maximum concentration of and was not detected in the
liver. However, it does not explain the presence of high 
concentrations of albendazole in the liver after the administration of 
albendazole sulphoxide to sheep. For albendazole to be found in liver 
after albendazole sulphoxide treatment, reduction at sulphur must have 
occurred. It has been reported (Duggan et al., 1980) that the
anti-inflammatory drug sulindac (a sulphoxide) undergoes irreversible 
oxidation to a sulphone. In addition, it undergoes reduction to a 
sulphide, a reaction which is readily reversible. The facile metabolic 
interconversion of fenbendazole (a sulphide) and oxfendazole (its 
corresponding sulphoxide) has also been reported (Marriner and Bogan, 
1981a and 1981b). It is extremely unusual for any drug metabolic 
reaction to be freely reversible, as it appears to contradict the 
purpose of drug metabolism, which is to make more polar metabolites.
In vitro experiments using bovine liver microsomes indicated 
that after microsomes were incubated with albendazole sulphoxide (for 
six hours), only 1.5% of the total drug was present as albendazole, 
the sulphoxide accounting for 95.4% of the total drug (Marriner, 
1980). Therefore, it is unlikely that liver residues of albendazole 
after the administration of albendazole sulphoxide to sheep were due 
to the reduction of albendazole sulphoxide in the liver. There is no 
evidence to suggest that sulphoxides are reduced to sulphides in the 
liver, either microsomally or non-miorosomally (Zeigler, 1982).
The possibility existed that albendazole sulphoxide was 
converted to albendazole by reduction in the rumen. The rumen is 
considered a purely reductive medium (Prins, 1985). No examples of
oxidation of drugs in the rumen are known. There has been one report 
recently that netobimin (a pro-drug of albendazole) is extensively 
oxidised to albendazole sulphoxide in the rumen, as much as 90% of the 
labelled material being present as albendazole sulphoxide twenty-four 
hours after the administratin of netobimin (McDougall et al., 1985). 
However, this result is in doubt, since albendazole sulphoxide was 
detected only in small amounts in ruminal fluid in this laboratory 
after the administration of netobimin (Bogan-Personal Communication). 
It is also apparent that if albendazole sulphoxide did account for 9056 
of the labelled material in the rumen, it would not be present in such 
a high percentage, as it has been demonstrated, in this laboratory, 
that albendazole sulphoxide is extensively reduced to albendazole in 
the rumen. When ruminal fluid was incubated in vitro with albendazole 
sulphoxide, conversion to the sulphide, albendazole, occurred (after 
twenty-four hours, 11.1% of the total drug present was albendazole) 
(Marriner, 1980). Albendazole was found in ruminal fluid (at a mean 
maximum concentration of 1.11 ug/ml) after the administration of 
albendazole sulphoxide to sheep. This may explain, in part, the high 
concentrations of albendazole found in liver after the administration 
of albendazole sulphoxide. Also, since the solubility of albendazole 
is lower than the solubility of albendazole sulphoxide, there may have 
been more conversion to albendazole than was measured in filtered 
ruminal fluid (i.e. some of the albendazole may have precipitated once 
formed).
Albendazole sulphoxide and albendazole sulphone were also 
detectable in tissues after both treatments to sheep. These residues
82
were not unexpected since, albendazole sulphoxide and albendazole 
sulphone are the major metabolites of albendazole found in the plasma 
(Marriner and Bogan, 1980) and urine (Gyurik et al., 1981) of sheep. 
Plasma concentrations of albendazole sulphoxide and albendazole 
sulphone were similar to those found in muscle after albendazole 
treatment.
Kidney samples were taken after the administration of 
albendazole sulphoxide to sheep (unfortunately this was not done after 
the administration of albendazole to sheep) and it was found that the 
sulphide albendazole was detectable in kidney, although residues were 
lower than those found in liver. This was surprising, but it is known 
that after albendazole treatment to sheep, some of the parent sulphide 
(1.0%) is excreted unchanged in the urine (Gyurik et al., 1981). 
Therefore, if albendazole was formed in the rumen after albendazole 
sulphoxide treatment, and was absorbed, it is reasonable to suggest 
that ruminal reduction is the source of sulphide in the kidney.
Albendazole sulphoxide and albendazole sulphone were also 
detectable in kidney. This was not unexpected since they are major 
urinary metabolites of albendazole in sheep (24.3% of an administered 
dose of albendazole was excreted as albendazole sulphoxide, and 3.4% 
was excreted as albendazole sulphone) (Gyurik et al., 1981).
From all the residue data for albendazole and albendazole 
sulphoxide in sheep, it was clear that if residues were present at 
five days post-treatment, they would be very low (less than 0.05 pg/g)
and therefore the meat witholding time of ten days for sheep treated 
with albendazole would seem to be adequate.
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It is interesting that in an experiment in which C-labelled 
albendazole was administered to sheep (DiCuollo et al.t 1977), 
extractable tissue residues did not fall below a concentration of 
0.1 pg/g until ten days post-treatment, although in this experiment
the dose of albendazole was 16 mg/kg (more than three times the
recommended dose). Unfortunately, tissue residue studies using 
radiolabelled drugs do not distinguish between parent drugs and their 
metabolites. Therefore, it is impossible to determine whether or not 
residues contain metabolites which may be toxic or metabolites which 
are non-toxic. It is important, in any drug residue study, that the 
exact nature of the residues be determined.
According to Parish et al., (1977), the longest residing
metabolite of albendazole in tissue is albendazole 2-aminosulphone. 
This metabolite is not anthelmintically active and it is not important 
toxicologically. In addition, in no tissue samples analysed in this 
laboratory did it constitute a quantitatively important metabolite. 
When measuring residues of albendazole, it was more important to 
monitor concentrations of the parent sulphide and the sulphoxide 
metabolite, since these two compounds could be the possible cause of 
toxicity to humans, especially now that albendazole has been made 
available for use in man in some countries, at a dose rate of 400 mg
per person (Morris et al., 1983).
CHAPTER 5
STUDIES WITH ALBENDAZOLE AND ALBENDAZOLE SULPHOXIDE
IN CATTLE
INTRODUCTION
Albendazole has a broad spectrum of activity against 
gastro-intestinal roundworms including inhibited larval stages, 
tapeworms, liver flukes and lungworms in cattle (Theodorides et al., 
1976). It is the first broad spectrum anthelmintic to have useful 
efficacy at low dose levels against all major economically important 
helminth parasites infecting domestic animals. In cattle, it is widely 
used in the control of gastro-intestinal nematodes and tapeworms, 
lungworms and liver flukes (Knight and Colglazier, 1977).
(For a more detailed introduction describing the metabolism and 
toxicity of albendazole and albendazole sulphoxide, please refer to 
Chapter 4).
MATERIALS AND METHODS
These studies involved the administration of albendazole and 
albendazole sulphoxide to cattle, both at a dose rate of 7.5 mg/kg. 
All treatments were by oral drench, and the animals were slaughtered 
at 1, 3, 5 and 8 days after albendazole treatment and 1,3 and 5 days 
after albendazole sulphoxide treatment. For both treatments, samples 
of liver, muscle nd kidney were taken at slaughter and stored
immediately at -20°C until assayed (as described in Chapter 3). They 
were assayed in duplicate (Tables 5.1 and -5.2).
In addition, milking cows were treated with albendazole and 
albendazole sulphoxide by oral drench, again both at a dose rate of
7.5 mg/kg. For the cows treated with albendazole, milk samples were 
taken before and at 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 
144 hours post-treatment. Both whole milk (Table 5.3) and the aqueous 
fraction of milk (Table 5.4) were analysed for residues. For the cows 
treated with albendazole sulphoxide, milk samples were taken before 
and at 12, 24 and 36 hours after treatment. Only whole milk
(Table 5.5) was analysed for residues. The samples provided to us did 
not allow a large enough volume to determine residues in the aqueous 
fraction of milk also.
RESULTS
After albendazole treatment (Table 5.1), albendazole itself was 
detectable in liver at one day post-treatment (at a concentration of
1.14 )Jg/g), but, at three days post-treatment, concentrations had 
fallen below a detectable level.
Albendazole sulphoxide was also detectable in liver at one day 
post-treatment (at a concentration of 0.43 pg/g), but again, at three 
days post-treatment, concentrations had fallen below a detectable 
level.
Albendazole sulphone was detectable in liver at one day 
post-treatment (at a concentration of 0.93 yg/g), but, like 
albendazole and albendazole sulphoxide, at three days post-treatment, 
concentrations had fallen below a detectable level.
In muscle, albendazole was not detectable at any time after 
treatment.
Albendazole suphoxide, like albendazole, was not detectable in 
muscle at any time after treatment.
Albendazole sulphone was detectable in muscle at one day 
post-treatment (although only a trace amount was present), but, at 
three days post-treatment, concentrations had fallen below a 
detectable level.
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In kidney, albendazole was not detectable at any time after 
treatment.
Albendazole sulphoxide, like albendazole, was not detectable in 
kidney at any time after treatment.
Albendazole sulphone was detectable in kidney at one day 
post-treatment (at a concentration of 0.21 pg/g), but, at three days 
post-treatment, concentrations had fallen below a detectable level.
TABLE 5.1 Liver, muscle and kidney residues of albendazole
and its metabolites in cattle.
LIVER
Residues (jig/g wet wt) 
Animal No Dose Days after Treatment ABZ ABSX ABSO
* * *
B65 7.5mg/kg 1 1.14 0.43 0.93
B85 7.5mg/kg 3 N.D. N.D. N.D.
B98 7.5mg/kg 5 N.D. N.D. N.D.
G81 7.5mg/kg 8 N.D. N.D. N.D.
MUSCLE
B65 7.5mg/kg 1 N.D. N.D. TRACE
B85 7.5mg/kg 3 N.D. N.D. N.D.
B98 7.5mg/kg 5 N.D. N.D. N.D.
G81 7.5mg/kg 8 N.D. N.D. N.D.
KIDNEY
B65 7.5mg/kg 1 N.D. N.D. 0.21
B85 7.5mg/kg 3 N.D. N.D. N.D.
B98 7.5mg/kg 5 N.D. N.D. N.D.
G81 7.5mg/kg 8 N.D. N.D. N.D.
ABZ = albendazole * = Mean values of two determinations.
ABSX = albendazole sulphoxide
ABSO = albendazole sulphone N.D. = Not detected (< 0.05 Jig/g) •
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After albendazole sulphoxide treatment (Table 5.2), albendazole 
sulphoxide was itself detectable in liver at one day post-treatment 
(at a concentration of 0.44 ^ ug/g in one calf, although only a trace 
amount was present in the other calf), but, at three days 
post-treatment, concentrations had fallen below a detectable level.
Albendazole sulphone was also detectable in liver at one day 
post-treatment (at a mean concentration of 3.58 pg/g), but, at three 
days post-treatment, concentrations had fallen below a detectable 
level.
Surprisingly, albendazole was detectable in liver at one day 
post-treatment (at a mean concentration of 3.98 pg/g), but, at three
days post-treatment, concentrations had fallen below a detectable
level.
In muscle, albendazole sulphoxide was not detectable at any time 
after treatment.
Albendazole sulphone was detectable in muscle at one day 
post-treatment (although only in one calf at a concentration of
1.15 pg/g; it was not detectable in the other calf), but, at three
days post-treatment, concentrations had fallen below a detectable
level.
Albendazole was not detectable in muscle at any time after
Q4
treatment.
In kidney, albendazole sulphoxide was detectable at one day 
post-treatment (although only in one calf at a concentration of 
0.54 jug/g; it was not detectable in the other calf), but, at three 
days post-treatment, concentrations had fallen below a detectable 
level.
Albendazole sulphone was also detectable in kidney at one day 
post-treatment (at a mean concentration of 2.64yug/g), but, at three 
days post-treatment, concentrations had fallen below a detectable 
level.
Again, surprisingly, albendazole was detectable in kidney at one 
day post-treatment (at a mean concentration of 1.52yug/g), but, at 
three days post-treatment, concentrations had fallen below a 
detectable level.
TABLE 5.2 Liver, muscle and kidney residues of albendazole 
sulphoxide and its metabolites in cattle.
LIVER
Residues fyig/g wet wt)
Animal No Dose Days after Treatment ABZ ABSX ABSO
78 7.5mg/kg 1 3.20 TRACE 1.30
B42 7.5mg/kg 1 4.76 0.44 5.86
A771 7.5mg/kg 3 N.D. N.D. N.D.
7243 7.5mg/kg 3 N.D. N.D. N.D.
534 7.5mg/kg 5 N.D. N.D. N.D
657 7.5mg/kg 5 N.D. N.D. N.D
MUSCLE
78 7.5mg/kg 1 N.D. N.D. N.D.
B42 7.5mg/kg 1 N.D. N.D. 1.15
A771 7.5mg/kg 3 N.D. N.D. N.D.
7243 7.5mg/kg 3 N.D. N.D. N.D.
534 7.5mg/kg 5 N.D. N.D. N.D
657 7.5mg/kg 5 N.D. N.D. N.D
KIDNEY
78 7.5mg/kg 1 1.68 N.D. 0.87
B42 7.5mg/kg 1 1.36 0.54 4.42
A771 7.5mg/kg 3 N.D. N.D. N.D.
7243 7.5mg/kg 3 N.D. N.D. N.D.
534 7.5mg/kg 5 N.D. N.D. N.D
657 7.5mg/kg 5 N.D. N.D. N.D
ABZ = albendazole N.D. = Not detected (< 0.05 ^ ig/g)
ABSX = albendazole sulphoxide 
ABSO = albendazole sulphone
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After albendazole administration to cows (Table 5.3), 
albendazole itself was not detectable in whole milk at any time after 
treatment.
Albendazole sulphoxide was detectable in whole milk. Maximum 
concentrations were reached at twleve hours post-treatment in both 
animals (0.24 jig/ml and 0.52 pg/ml).
In one of the cows, albendazole sulphoxide was still detectable 
at twenty-four hours post-treatment (at a concentration of 
0.04 pg/ml), but, at thirty-six hours post-treatment, concentrations 
had fallen below a detectable level.
In the other cow, albendazole sulphoxide was still detectable at 
thirty-six hours post-treatment (at a concentration of 0.07 jig/ml), 
but, at forty-eight hours post-treatment, concentrations had fallen 
below a detectable level.
Albendazole sulphone was also detectable in whole milk. Maximum 
concentrations were reached at twelve hours post-treatment in both 
animals (1.44 jig/ml and 2.18 jig/ml).
In both cows, albendazole sulphone was still detectable at 
twenty-four hours post-treatment (0.04 pg/ml and 0.03 pg/ml), but, at 
thirty-six hours post-treatment, concentrations had fallen below 
detectable levels.
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In the aqueous fraction of milk (Table 5.4), albendazole itself 
was not detectable at any time after treatment.
Albendazole sulphoxide was detectable in the aqueous fraction of 
milk. Maximum concentrations were reached at twelve hours 
post-treatment in both animals (0.l8jug/ml and 0.14 jig/ml).
In one of the cows, albendazole sulphoxide was still detectable 
at twenty-four hours post-treatment (at a concentration of 
0.04 jj.g/ml), but, at thirty-six hours post-treatment, concentrations 
had fallen below detectable levels.
In the other cow,albendazole sulphoxide was still detectable at 
thirty-six hours post-treatment (at a concentration of 0.02 jig/ml), 
but, at forty-eight hours post-treatment, concentrations had fallen 
below a detectable level.
Albendazole sulphone was also detectable in the aqueous fraction 
of milk. Maximum concentrations were reached at twelve hours 
post-treatment (0.01 jig/ml for both cows), but, at thirty-six hours 
post-treatment, concentrations had fallen below detectable levels.
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TABLE 5.3 Milk residues (whole milk) of albendazole
and its metabolites in two cows.
CONCENTRATION fog/ml)
TIME(h) ALBENDAZOLE ALBENDAZOLE ALBENDAZOLE
SULPHOXIDE SULPHONE
0 0.00 0.00 0.00 A
0.00 0.00 0.00 B
12 N.D. 0.24 1.44 A
N.D. 0.52 2.18 B
24 N.D. 0.07 0.04 A
N.D. 0.04 0.03 B
36 N.D. 0.07 N.D. A
N.D. N.D. N.D. B
48 N.D. N.D. N.D. A
N.D. N.D. N.D. B
60 N.D. N.D. N.D. A
N.D. N.D. N.D. B
72 N.D. N.D. N.D. A
N.D. N.D. N.D. B
84 N.D. N.D. N.D. A
N.D. N.D. N.D. B
96 N.D. N.D. N.D. A
N.D. N.D. N.D. B
108 N.D. N.D. N.D. A
N.D. N.D. N.D. B
120 N.D. N.D. N.D. A
N.D. N.D. N.D. B
132 N.D. N.D. N.D. A
N.D. N.D. N.D. B
144 N.D. N.D. N.D. A
N.D. N.D. N.D. B
[.D.
< 0.
= not detected 
05 fig/ml)
A = cow No.205 B = cow No.206
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TABLE 5.4 Milk residues (aqueous fraction) of albendazole
and its metabolites in two cows.
CONCENTRATION fog/ml)
TIME(h) ALBENDAZOLE ALBENDAZOLE ALBENDAZOLE
SULPHOXIDE SULPHONE
0 0.00 0.00 0.00 A
0.00 0.00 0.00 B
12 N.D. 0.18 0.52 A
N.D. 0.14 0.37 B
24 N.D. 0.05 0.01 A
N.D. 0.04 0.01 B
36 N.D. 0.02 N.D. A
N.D. N.D. N.D. B
48 N.D. N.D. N.D. A
N.D. N.D. N.D. B
60 N.D. N.D. N.D. A
N.D. N.D. N.D. B
72 N.D. N.D. N.D. A
N.D. N.D. N.D. B
84 N.D. N.D. N.D. A
N.D. N.D. N.D. B
96 N.D. N.D. N.D. A
N.D. N.D. N.D. B
108 N.D. N.D. N.D. A
N.D. N.D. N.D. B
120 N.D. N.D. N.D. A
N.D. N.D. N.D. B
132 N.D. N.D. N.D. A
N.D. N.D. N.D. B
144 N.D. N.D. N.D. A
N.D. N.D. N.D. B
N.D. = not detected A = cow No.205 B = cow No.206
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After albendazole sulphoxide treatment of cows (Table 5.5), 
albendazole sulphoxide itself was detectable in whole milk. Maximum 
concentrations were reached at twelve hours post-treatment in four of 
the cows (a mean concentration of 0.12^ig/ml), but, at twenty-four 
hours post-treatment, concentrations had fallen below a detectable 
level.
In the other cow, albendazole sulphoxide was detectable in whole 
milk at twelve hours post-treatment (at a concentration of 
0.11 pg/ml), but, maximum concentrations were reached at twenty-four 
hours post-treatment (a concentration of 0.18 jig/ml). At thirty-six 
hours post-treatment, concentrations had fallen below a detectable 
level.
Albendazole sulphone was also detectable in whole milk. Maximum 
concentrations were reached at twelve hours post-treatment in all five 
cows (a mean concentration of 0.46 jig/ml). At twenty-four hours 
post-treatment, concentrations had fallen below a detectable level in 
four of the cows.
In the other cow, albendazole sulphone was still detectable at 
twenty-four hours post-treatment (although only a trace amount was 
present), but, at thirty-six hours post-treatment, concentrations had 
fallen below a detectable level.
Albendazole was not detectable in whole milk at any time after 
treatment.
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TABLE 5.5 The concentration (pg/ml) of albendazole sulphoxide (ABSX) 
and albendazole sulphone (ABSO) in milk at intervals 
after oral administration of albendazole sulphoxide at 
a dose rate of 7.5 mg/kg.
TIME POST-TREATMENT (hours)
)W NO 0 12 24 36
1 ABSX N.D. 0.26 N.D. N.D.
ABSO N.D. 0.73 N.D. N.D.
6 ABSX N.D. 0.11 N.D. N.D.
ABSO N.D. 0.53 N.D. N.D.
19 ABSX N.D. 0.06 N.D. N.D.
ABSO N.D. 0.28 N.D. N.D.
33 ABSX N.D. 0.06 N.D. N.D.
ABSO N.D. 0.32 N.D. N.D.
45 ABSX N.D. 0.11 0.18 N.D.
ABSO N.D. 0.45 TRACE N.D.
N.D. = Not detected
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DISCUSSION
After the administration of albendazole or albendazole 
sulphoxide to cattle, residues were similar qualitatively and 
quantitatively. With both treatments, concentrations of albendazole, 
albendazole sulphoxide and albendazole sulphone in tissues were much 
lower than those found in sheep tissues. In addition, residues did not
persist as long as they did in sheep. In general, cattle have a
greater capacity for the oxidation of benzimidazoles than sheep do, 
and in the case of albendazole, the conversion of the sulphoxide to 
the sulphone metabolite is more rapid and complete in cattle than in 
sheep. Therefore, since this conversion is irreversible (Gyurik et_
al., 1981), it was not surprising that no detectable residues of
albendazole sulphoxide were found in muscle after both treatments. 
This increased oxidative capacity of cattle for benzimidazoles may 
also explain the finding that liver residues of albendazole and 
albendazole sulphoxide were much lower in cattle than in sheep. The 
finding that residues of the sulphide were detectable in liver after 
both treatments was surprising, because albendazole itself does not 
circulate in the plasma of cattle after these treatments. In the case 
of albendazole treatment, it was probable that unchanged albendazole 
was absorbed and bound in the liver (as has already been discussed for 
albendazole residues in sheep liver), but this does not explain 
residues of the sulphide after albendazole sulphoxide treatment. In 
this case, it was probable that albendazole sulphoxide was reduced to 
albendazole to some extent in the rumen (as has been shown to occur in 
sheep) and the newly-formed albendazole absorbed and bound in the 
liver.
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With both treatments, it would appear that liver residue 
concentrations were higher than muscle and kidney residue 
concentrations (although kidney residues were higher than those found 
in muscle). It would seem that the concentrations of liver residues 
were around twice the amount of those found in kidney, which were 
around four times greater than those found in muscle.
Albendazole was detectable in kidney after the administration of 
albendazole sulphoxide. Albendazole residues were not unexpected in 
kidney, as it is known that after albendazole treatment of cattle, 
some of the parent sulphide (0.1%) is excreted unchanged in the urine 
(Gyurik et al., 1981).
From all the residue data for albendazole and albendazole 
sulphoxide in cattle, it was clear that if residues were present at 
three days post-treatment, they would be very low (less than 
0.05 fig/g) and therefore the meat witholding time of fourteen days for 
cattle treated with albendazole would seem to be adequate.
Delatour et al., (1984) have pointed out that in recent years, 
an increasing number of drugs have been reported for which metabolism 
includes some covalent binding of metabolites to macromolecules, which 
gives rise to non-extractable tissue-bound residues. These residues 
are often the result of highly reactive intermediates which have only 
been isolated in the last few years. Isolation is difficult because of 
their highly reactive nature. These tissue-bound residues are of 
considerable interest because of their possible participation in
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target species toxicity, as well as their potential toxicological 
significance in terms of food hygiene for humans.
In these studies with albendazole and albendazole sulphoxide, 
the extraction procedure used involved boiling the tissues in strong 
acid (see Chapter 3). Therefore, any drug-related bound residues would 
have been extractable and hence, detectable. It has been shown 
(Delatour et al., 1984) that bound residues of albendazole do not 
appear to have any toxicological significance because they are 
strongly covalently bound and therefore they are not absorbed.
Toxicity of residues is related to the pharmacokinetics of the parent
sulphide and its free metabolites.
Milk was free of residues of the sulphide albendazole after the - 
administration of albendazole or albendazole sulphoxide to cows.
Albendazole sulphoxide and albendazole sulphone were detectable 
in milk after both treatments. These results were not surprising 
since, albendazole sulphoxide and albendazole sulphone were the major 
metabolites found in cattle plasma after both treatments.
The interesting finding was that after the administration of
albendazole to cows, residues in the aqueous fraction of milk were 
very similar to those found in whole milk. Maximum concentrations were 
found at twelve hours post-treatment in both cases and the residue 
profiles were identical. From the results it seems that after
albendazole treatment, residues of albendazole sulphoxide and
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albendazole sulphone were almost exclusively associated with the 
aqueous fraction of milk. These results are important in that in the 
manufacture of cream, cheese and other milk products, the lipid 
fraction of milk is used. Therefore, if residues are associated with 
the aqueous fraction of milk, they would pose less of a problem to the 
consumer of these products.
From all the residue data for albendazole and albendazole 
sulphoxide in cows' milk, it was clear that residues did not persist 
beyond thirty-six hours (if residues were present beyond this time, 
they would be very low: less than 0.05^ig/ml). Therefore, the milk 
witholding time of seventy-two hours for cattle treated with 





-5-(phenyl-thio)- phenyl-2-methoxy-acetamide) is a broad spectrum 
anthelmintic which is active against gastro-intestinal roundworms and 
lungworms in sheep and cattle, and many other species (Behrens, 1978; 
Burger, 1978; Corba, 1981; Ciordia et al., 1982; Dimitrov et al., 
1982). It is a member of the pro-benzimidazole group of anthelmintics.
The metabolism of febantel has been extensively studied (Delatour 
et al., 1982b), with nine metabolites being identified in the urine of 
sheep and rats which had been given febantel orally (Figure 6.1). 
Febantel is metabolised by cyclization, oxidation at sulphur, aromatic 
hydroxylation and carbamate hydrolysis. The mechanism of cyclization is 
poorly understood. It has been suggested that it is mono-oxygenase 
dependent (Douch et al., 1974), but it seems more likely that 
cyclization occurs to a great extent in the gut (i.e. before absorption 
has taken place) (Bogan, Personal Communication). It is known that 
febantel undergoes hydrolytic removal of a methoxyacetyl group prior to 
cyclization to a benzimidazole (in this case fenbendazole).
After cyclization, the most important metabolic reactions leading 
to the observed urine metabolites were oxidation at sulphur and 
carbamate hydrolysis. Apart from metabolite A (which is a sulphide), 
the important urinary metabolites were all sulphoxides or sulphones. 
The oxidation of alkyl and aryl sulphides to more polar sulphoxides and 
sulphones is commonly observed and facilitates urinary excretion 
(Duggan et al., 1977).
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In sheep and rats, the most abundant urinary metabolites were: 
metabolite A (fenbendazole), metabolite A* (the sulphoxide of febantel, 
which cyclizes to oxfendazole), metabolite C (oxfendazole) and 
metabolite B (oxfendazole sulphone).
When sheep were given febantel orally at a dose rate of
7.5 mg/kg, fenbendazole, oxfendazole and oxfendazole sulphone were all 
detectable in plasma. Febantel itself was also detectable in plasma, 
although only in very low concentrations (less than 0.05 yug/ml) 
(Delatour et al., 1985a).
When cattle were given febantel orally at a dose rate of
7.5 mg/kg, fenbendazole, oxfendazole and oxfendazole sulphone were also 
detectable in plasma. In addition, febantel and its sulphoxide 
metabolite were also detectable in plasma (Delatour et al., 1985a).
Fenbendazole and oxfendazole have also been identified in the 
milk of cows treated with febantel at a dose rate of 7.5 mg/kg 
(Delatour et al., 1983b).
In sheep, fenbendazole, oxfendazole and oxfendazole sulphone are 
also found in plasma after the administration of oxfendazole (Marriner 
and Bogan, 1981a) and fenbendazole (Marriner and Bogan, 1981b). 
Similarly, in cattle, fenbendazole, oxfendazole and oxfendazole 
sulphone are found in plasma after the administration of oxfendazole 
and fenbendazole (Ngomuo et al., 1984). From these results, it is clear 
that fenbendazole, oxfendazole and oxfendazole sulphone are the major
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metabolites of each of these three anthelmintics (febantel, 
fenbendazole and oxfendazole).
The facile metabolic interconversion of alkyl aryl sulphides has 
been reported (Duggan et al., 1980) and this is known to occur with 
fenbendazole and oxfendazole (Marriner and Bogan, 1981a and 1981b), 
although the metabolic oxidation of sulphoxides (i.e. oxfendazole) to 
sulphones (i.e. oxfendazole sulphone) appears to be irreversible (Kexel 
and Schmidt, 1972).
Regarding toxicity, febantel is well tolerated in all domestic 
animals. It has been extensively studied with regard to its teratogenic 
potential, since one of its metabolites (oxfendazole) which is itself 
marketed, has been shown to be teratogenic.
From the teratogenic point of view, febantel is said to be safe 
in the ewe at an oral dosage of 10 mg/kg (Terblanche, 1979), while at 
45 mg/kg administered as a single dose on day seventeen of pregnancy, 
renal and skeletal abnormalities occurred in more than ten per cent of 
the lambs (Chement, 1982). Metabolite C (oxfendazole) was not 
teratogenic in sheep at doses of 7.5 mg/kg, 10 mg/kg and 15 mg/kg, but, 
at doses of 22.5 mg/kg and 25 mg/kg on day seventeen of pregnancy, it 
induced embryolethality and malformations (Delatour et al., 1977; 
Piercy et al., 1979). The study of the embryotoxic effects of 
individual metabolites of oxfendazole has indicated that the parent 
compound seems to be responsible for the observed teratogenicity 
(Delatour et al., 1982a). Oxfendazole (metabolite C) is also the 
ultimate teratogen of febantel (Delatour et al., 1982b).
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In the rat, febantel, metabolite A1 (the sulphoxide of febantel) 
and metabolite C (oxfendazole) have been found to be teratogenic 
(Delatour et al., 1982b).
From all this toxicological data, it is clear that in any residue 
studies involving febantel, it is most important that the parent 
compound should be measured, as should metabolite A' (febantel 
sulphoxide) and metabolite C (oxfendazole). In addition, metabolite A 
(fenbendazole) should be measured as it is readily interconvertible 
with metabolite C (oxfendazole).
In the following experiment with febantel, metabolite A,
metabolite B (oxfendazole sulphone) and metabolite C were measured 
(Figure 6.2). The reason for measuring metabolite B was that, although 
it is not toxicologically important, it is a major metabolite of 
febantel in the plasma of sheep (Delatour et al., 1985a). Also, under 
the chromatographic conditions used to measure metabolite C, 
metabolite B is easily measured. Unfortunately, the method used did not 
allow the determination of febantel itself, but, since it is detectable 
in plasma only in very low concentrations after its administration to 
sheep at a dose rate of 7.5 mg/kg (Delatour et al., 1985a), it is 
unlikely that it would be detectable in plasma in this experiment (in 
which the sheep were dosed at 5 mg/kg). Furthermore, the 
chromatographic conditions used for the determination of metabolites A,
B and C, did not allow for the determination of metabolite A ’.
In this experiment, the animals were slaughtered at various times
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after the administration of febantel. Liver, muscle and plasma were 
analysed for residues until they could no longer be detected (limits of 
detection 0.05 yag/g for tissues and 0.05 jtig/ml for plasma). Table 6.1 
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TABLE 6.1 The meat and milk witholding times for febantel 











RESIDUES OF THE MAJOR METABOLITES OF FEBANTEL IN THE TISSUES OF SHEEP
In this experiment, five sheep were given febantel orally, at a 
dose rate of 5 mg/kg (recommended dosage) (Table 6.2). They were 
slaughtered at 1, 7, 14, 21 and 28 days post-treatment.
Samples of liver and muscle were taken at slaughter and stored 
immediately at -20°C until assayed (as described in Chapter 3).
Blood samples were also taken at intervals throughout the course 
of the experiment to assess the tissue/plasma ratio of residues; plasma
was removed after centrifugation and stored at -20°C until assayed.
All liver and muscle samples were assayed in duplicate 
(Tables 6.3 and 6.4).
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TABLE 6.2 Weights, dose volumes and dosages for the
five sheep used in the febantel residue study
SHEEP NO. WT.(kg) VOL. SUSPENSION TOTAL DOSE DOSE RATE
2.5% w/v (ml) (mg) (mg/kg)
123 72 14.4 360 5
88 75 15.0 375 5
89 68 13.6 340 5
90 84 16.8 420 5
102 77 15.4 385 5
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TABLE 6.3 Liver residues of febantel metabolites in sheep
Residues Qug/g wet wt)
Days after
Animal No Dose Treatment Fenbendazole Oxfendazole Oxfendazole
Sulphone
* (4.89) (4.05) (1.42)
123 5mg/kg 1 5.02 4.05 1.40
(5.16) (4.05) (1.38)
(1.30) (2.86) (0.25)
88 5mg/kg 7 1.09 2.66 0.20
(0.88) (2.33) (0.15)
(0.30) (0.57)
89 5mg/kg 14 0.28 0.50 N.D.
(0.26) (0.42)
(0.15)
90 5mg/kg 21 N.D. 0.12 N.D,
(0.10)
102 5mg/kg 28 N.D. N.D. N.D.
* = Mean value of two determinations
























FIGURE 6.3 Semi-logarithmic plot of liver residues of 
fenbendazole and oxfendazole after the 
administration of fenbendazole to sheep.
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TABLE 6.4 Muscle residues of febantel metabolites in sheep
Residues (jag/g wet wt)
Days after
Animal No Dose Treatment Fenbendazole Oxfendazole Oxfendazole
Sulphone
* (0.35) (0.16) (0.14)
123 5mg/kg 1 0.41 0.16 0.14
(0.47) (0.17) (0.14)
88 5mg/kg 7 N.D. Trace N.D.
89 5mg/kg 14 N.D. N.D. N.D.
90 5mg/kg 21 N.D. N.D. N.D.
102 5mg/kg 28 N.D. N.D. N.D.
* = Mean value of two determinations
N.D. = Not detected
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TABLE 6.5 Plasma concentrations of febantel metabolites in sheep
Concentration (lig/ml)
Days after
Animal Dose Treatment Febantel Fenbendazole Oxfendazole Oxfendazole 
No Sulphone
123 5mg/kg 1 N.D. 0.07 0.29 0.32
88 5mg/kg 7 N.D. N.D. N.D. N.D.
89 5mg/kg 14 N.D. N.D. N.D. N.D.
90 5mg/kg 21 N.D. N.D. N.D. N.D.
102 5mg/kg 28 N.D. N.D. N.D. N.D.
N.D. = Not detected
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After febantel treatment, fenbendazole was detectable in liver in 
high concentrations at one day post-treatment (a concentration of
fenbendazole was still detectable (at a concentration of 0.28 jig/g), 
but, at twenty-one days post-treatment, concentrations had fallen below 
a detectable level.
Oxfendazole was also detectable in liver in high concentrations 
at one day post-treatment (a concentration of 4.05 ^ ig/g). Again, 
residues persisted and at twenty-one days post-treatment oxfendazole 
was still detectable (at a concentration of 0.12 jig.g), but, at 
twenty-eight days post-treatment, concentrations had fallen below a 
detectable level.
Oxfendazole sulphone was detectable in liver at one day 
post-treatment (at a concentration of 1.40 . I t  was still
detectable at seven days post-treatment (at a concentration of
fallen below a detectable level.
A semi-logarithmic representation of the concetrations of 
fenbendazole and oxfendazole in liver versus time, after the 
administration of febantel, was plotted (Figure 6.3). Linear regression 
analysis revealed straight lines for both compounds (R = 0.997 for 
fenbendazole and 0.984 for oxfendazole) indicating first-order 
elimination.
5.02 ^ ig/g). Residues persisted and at fourteen days post-treatment
but, at fourteen days post-treatment, concentrations had
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In muscle, fenbendazole was detectable at one day post-treatment 
(at a concentration of 0.41 ug/g), although in a much lower 
concentration than was found in liver at the same time. Residues did
not persist and at seven days post-treatment, concentrations had fallen
below a detectable level.
Oxfendazole was also detectable in muscle at one day 
post-tretment (at a concentration of 0.16 ^ ig/g). At seven days 
post-tretment it was still detectable (although only a trace amount was 
present), but, at fourteen days post-treatment, concentrations had 
fallen below a detectable level.
Oxfendazole sulphone was detectable in muscle at one day
post-treatment (at a concentration of 0.14 jig/g). Residues did not 
persist and at seven days post-treatment, concentrations had fallen 
below a detectable level.
In plasma (Table 6.5), fenbendazole was detectable at one day 
post-treatment (at a concentration of 0.07 jug/ml). Residues did not 
persist and at seven days post-treatment, concentrations had fallen 
below a detectable level.
Oxfendazole was also detectable in plasma at one day
post-treatment (at a concentration of 0.29 yug/ml). Again, residues did 
not persist and at seven days post-treatment, concentrations had fallen 
below a detectable level.
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Oxfendazole sulphone was detectable in plasma at one day
post-treatment (at a concentration of 0.32^ig/ml). As with fenbendazole
and oxfendazole, residues did not persist and at seven days
post-treatment, concentrations had fallen below a detectable level.




After the administration of febantel to sheep, its major 
metabolites (fenbendazole, oxfendazole and oxfendazole sulphone) were 
detectable in liver in high concentrations. Fenbendazole and 
oxfendazole persisted in liver. At fourteen days post-treatment, 
fenbendazole was still detectable, but oxfendazole persisted longer, 
and was still detectable at twenty-one days post-treatment. Febantel is 
considered a pro-drug of fenbendazole and oxfendazole. Therefore, one 
might expect the residue profile of febantel to be similar to the 
profiles of fenbendazole and oxfendazole. This is in fact the case (see 
Chapters 7 and 8), residues of oxfendazole being detectable in liver at 
twenty-one days after the administration of both fenbendazole 
(Chapter 7) and oxfendazole (Chapter 8).
In muscle, concentrations of these metabolites were very low 
compared to those found in liver, and they did not persist as long (at 
seven days post-treatment only a trace amount of oxfendazole was 
detectable in muscle).
In plasma, concentrations of these metabolites were also very 
low (similar to those found in muscle). At seven days post-tretment, 
concentrations of fenbendazole, oxfendazole and oxfendazole sulphone 
had fallen below detectable levels. Febantel itself was not detectable 
in plasma at any time after treatment. This was not surprising since, 
after the administration of febantel to sheep at a dose rate of
7.5 mg/kg, the parent compound was detectable only in very low
concentrations (a maximum (Delatour etal.,
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1985a). Therefore, it is very unlikely that it would be detectable in 
plasma after a dose of 5 mg/kg.
From these results, it seems clear that residues of the 
metabolites of febantel are high and persist well beyond the 
recommended meat withholding time of eight days for sheep treated with 
febantel. Therefore, an eight day withholding time may be inadequate, 
especially considering that the metabolite which is still detectable in 
liver at twenty-one days post-treatment (oxfendazole) is a known 
teratogen. However, since the teratogenic and embryotoxic effects of 
oxfendazole are dose-related, a determination of a NEL, followed by a 
calculation of an ADI for a certain safety factor would be required to 
determine the minimum withholding period. Also involved is a 
consideration of the relationship between residue concentration and 
time. The elimination of oxfendazole from the liver of sheep treated 
with febantel is first-order (Figure 6.3), and the extrapolation of 
these results indicates that perhaps a twenty-one day withholding time 
would ensure a greater degree of safety. Furthermore, any complete 
determination of withholding periods for these compounds must include 
relay-toxicity studies involving absorption, elimination and toxic 
effects of residues in monogastric animals. Such studies would 
determine whether they are absorbed from contaminated food and whether 





Fenbendazole (methyl-5-(phenylthio)-2-benzimidazole carbamate) 
is a potent member of the benzimidazole group of anthelmintics. It was 
the first anthelmintic which proved to be effective against inhibited 
larval stages of the important parasite of cattle Ostertagia ostertagi 
(Duncan et al., 1976). It has also been shown to be extremely 
effective against lungworms in cattle (Duwel, 197*0 and sheep (Ross, 
1975), and has also been shown to have some activity against tapeworms 
and liver flukes (Corba et al., 1979).
The metabolism and pharmacokinetics of fenbendazole have been 
studied in various species. Fenbendazole has been measured in the 
plasma of cattle, sheep and other species (Duwel et al., 1975) using a 
fluorimetric method which unfortunately did not distinguish the parent 
drug from its metabolites. Similarly, plasma and abomasal fluid
14concentrations of C-labelled fenbendazole have been reported m  
cattle after intra-ruminal administration (Prichard et al., 1978), but 
again, the method did not distinguish between the parent drug and its 
metabolites. Duwel (1977) has also reported on the terminal 
14metabolites of C-labelled fenbendazole in sheep and cattle, but
plasma concentrations of its metabolites were not reported. The
principal metabolite in sheep and cattle urine results from 
hydroxylation of the phenyl ring, although carbamate hydrolysis also 
occurs to some extent. In pig urine, the quantity of metabolites is 
higher and two other metabolites are present (which are not present in 
sheep and cattle urine), one of which is a hydroxyl derivative.
Metabolites of fenbendazole are also excreted in the faeces (Duwel,
1977).
131
After the administration of fenbendazole to sheep (Marriner and 
Bogan, 1981b), the parent sulphide was detected in plasma along with 
the sulphoxide metabolite (oxfendazole) and the sulphone metabolite 
(oxfendazole sulphone). Similarly, after the administration of 
fenbendazole to cattle (Ngomuo et al., 1984), oxfendazole and
oxfendazole sulphone were found to be the major plasma metabolites.
In the horse, oxfendazole and oxfendazole sulphone were also 
found to be the major plasma metabolites after fenbendazole 
administration (Marriner and Bogan, 1985).
Oxfendazole is also detectable in pig plasma after fenbendazole 
administration (Anonymous, 1984).
It has been reported (Anonymous, 1983) that at one day after a
14
cow was given C-labelled fenbendazole at a dose rate of 10 mg/kg, 
total liver residues were 17.6 Jig/g, of which approximately Q0% was 
fenbendazole and 6$ was oxfendazole. Duwel (1977) has reported on 
total tissue and milk residues of fenbendazole. Residues in cows’ milk 
were low after the administration of fenbendazole at a dose rate of
7.5 mg/kg. Maximum concentrations were 0.30 ^ ig/ml at twenty-eight 
hours post-treatment, and at fifty-four hours post-treatment, residues 
could no longer be detected (limit of detection of 0.05 yag/ml).
In sheep, cattle and pigs treated with fenbendazole at
recommended dose rates, residues were low in most tissues after two
days, and approached the limit of detection (0.05 jug/g) at five days.
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However, residues were somewhat higher in the liver and persisted for 
up to fourteen days.
These residue studies did not distinguish fenbendazole itself 
from its important metabolites oxfendazole and oxfendazole sulphone. 
Fenbendazole and oxfendazole are metabolically interconvertible. 
Therefore, when fenbendazole is administered, oxfendazole should be 
measured as a matter of course.
Toxicity studies have revealed that the sulphoxide metabolite of 
fenbendazole (oxfendazole) may be important as regards teratogenicity. 
Investigations have shown that fenbendazole is well tolerated in the 
host animal. In toxicity tests involving a single administration to 
small rodents, it was not possible to determine the minimum lethal 
dose. The oral is certainly greater than 10,000 mg/kg in rats and
mice (Duwel, 1977).
Apart from transient and dose-dependent increases of individual 
transaminases (cytosolic liver enzymes which indicate hepatotoxicity 
when found in plasma) in a few members of each group of animals 
treated, no side-effects were observed. In sheep, a single oral dose 
of 5,000 mg/kg was well tolerated, and in cattle, a single oral dose 
of 2,000 mg/kg was well tolerated (Duwel, 1977).
In sheep, fenbendazole is not teratogenic (Becker, 1975), but 
its sulphoxide metabolite (oxfendazole) has been shown to be 
teratogenic (Delatour et al., 1977).
133
Neither fenbendazole (Becker, 1975) nor oxfendazole (Piercy et 
al., 1979) have been shown to be teratogenic in cattle.
Pigs have been reported to be insensitive with respect to the 
teratogenicity of fenbendazole (Anonymous, 1984) and oxfendazole 
(Morgan, 1982) during the first month of pregnancy.
No teratogenic effects have been observed for fenbendazole 
(Becker, 1975) or oxfendazole (Anonymous, 1978) in the horse.
Fenbendazole appears to be non-teratogenic in the rat (Baeder et 
al., 1974). However, embryolethal and teratogenic effects have been 
observed for oxfendazole in the rat (Delatour et al., 1977).
It has also been reported that fenbendazole is embryotoxic but 
not teratogenic in rabbits at a dose of 63 mg/kg (Anonymous, 1984).
The reason that fenbendazole is not teratogenic is probably that 
because it is very insoluble, insufficient can dissolve (no matter how 
high the dose) to result in blood concentrations sufficiently high to 
produce toxic effects (Marriner and Bogan, 1981b). It has also been 
demonstrated that the sulphone metabolite of fenbendazole is not 
teratogenic (Delatour et al., 1982a).
From this toxicological data, it is clear that in any residue 
studies involving fenbendazole, it is most important that the parent 
sulphide (fenbendazole) should be measured, as should the sulphoxide
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metabolite (oxfendazole), since none of the other metabolites of 
fenbendazole have been found to be toxic. Although fenbendazole itself 
is not teratogenic, it is readily interconvertible with oxfendazole 
(which is teratogenic), hence, it is important that both compounds are 
measured.
In the following experiments with fenbendazole, the parent 
sulphide, and the sulphoxide and sulphone metabolites were measured 
(Figure 7.1). The reason for measuring oxfendazole sulphone was that, 
although it is not toxicologically important, it is a major metabolite 
of fenbendazole in the plasma of sheep (Marriner and Bogan, 1981b) and 
cattle (Ngomuo et al., 1984). Also, under the chromatographic 
conditions used to measure oxfendazole, oxfendazole sulphone is easily 
measured.
In all experiments, the animals were slaughtered at various 
times after the administration of fenbendazole. Liver, muscle, milk 
and plasma were analysed for residues of fenbendazole and its 
metabolites until they could no longer be detected (limits of 
detection 0.05 yug/g for tissues and 0.05 yug/ml for mlik and plasma). 
It was also assessed whether or not residues persisted beyond 
recommended withdrawal periods (Table 7.1).
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FIGURE 7.1 Fenbendazole and its important metabolites.
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These studies involved the administration of fenbendazole to 
sheep at a dose rate of 5 mg/kg as an oral drench. The animals were 
slaughtered at 24 hours, 4, 8, 14, 21 and 28 days post-treatment.
Samples of liver and muscle were taken at slaughter and stored
immediately at -20°C until assayed (as described in Chapter 3)- They 
were assayed in duplicate (Table 7.2). Blood samples were also taken 
at intervals throughout the course of the experiment to assess 
tissue/plasma ratios; plasma was removed after centrifugation and
stored at -20°C until assayed (Table 7*2),.
In addition, milking cows were treated with fenbendazole by oral 
drench, at a dose rate of 7.5 mg/kg. Milk samples were taken before 
and at 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144 hours
after treatment. Both whole milk (Table 7.3) and the aqueous fraction 
of milk (Table 7.4) were analysed for residues.
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RESULTS
After fenbendazole treatment of sheep (Table 7.2), fenbendazole 
itself was detectable in liver in high concentrations at one day
at fourteen days post-treatment fenbendazole was still detectable (at
concentrations had fallen below a detectable level.
Oxfendazole was also detectable in liver in high concentrations 
at one day post-treatment (a concentration of 5.54yug/g), although 
highest concentrations were detectable at four days post-treatment (a 
concentration of 12.15^ug/g). Again, residues persisted and at 
twenty-one days post-treatment oxfendazole was still detectable (at a 
concentration of 0.33yug/g), but, at twenty-eight days post-treatment, 
concentrations had fallen below a detectable level.
Oxfendazole sulphone was detectable in liver at one day 
post-treatment (at a concentration of 0.78 pg/g). It was still 
detectable at fourteen days post-treatment (althougn only a trace 
amount was present), but, at twenty-one days post-treatment, 
concentrations had fallen below a detectable level.
A semi-logarithmic representation of the concentrations of 
fenbendazole and oxfendazole in liver versus time, after the 
administration of fenbendazole, was plotted (Figure 7.2). Linear 
regression analysis revealed straight lines for both compounds 
(R=0.974 for fenbendazole and 0.999 for oxfendazole), indicating
post-treatment (a concentration
a concentration of 0.38 ug/g), but, at twenty-one days post-treatment,
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first-order elimination.
In muscle, fenbendazole was detectable at one day post-treatment
concentration than was found in liver at the same time. At four days 
post-treatment it was still detectable (although only a trace amount 
was present), but, at eight days post-treatment, concentrations had
fallen below a detectable level.
Oxfendazole was also detectable in muscle at one day
post-treatment (although only a trace amount was present). At fouur 
days post-treatment, concentrations had fallen below a detectable 
level.
Oxfendazole sulphone was detectable in muscle at one day
post-treatment (at a concentration of 0.15yug/g). It was still
detectable at four days post-treatment (at a concentration of
0.08 jig/g), but, at eight days post-treatment, concentrations had 
fallen below a detectable level.
In plasma (Table 6.5), fenbendazole was detectable at one day
post-treatment (at a concentration of 0.l6yug/ml). It was still
detectable at four days post-treatment (at a concentration of
0.03jug/ml), but, at eight days post-treatment, concentrations had
fallen below a detectable level.
Oxfendazole was also detectable in plasma at one day
(at a concentration of although in a much lower
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post-treatment (at a concentration of 0.29 yug/ml), but, at four days 
post-treatment, concentrations had fallen below a detectable level.
Oxfendazole sulphone was detectable in plasma at one day 
post-treatment (at a concentration of 0.07 jug/ml), but again, at four 
days post-treatment, concentrations had fallen below a detectable 
level.
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TABLE 7.2 Liver, muscle and plasma residues of fenbendazole
and its metabolites in sheep
LIVER
Residues (yug/g wet wg) 
Animal No Dose Days After Treatment FBZ OFZ OFZ.SO
* * *
100 5mg/kg 1 8.88 5.54 0.78
101 5mg/kg 4 5.60 12.14 0.84
99 5mg/kg 8 0.93 3.49 0.23
32 5rag/kg 14 0.38 0.52 TRACE
47 5mg/kg 21 N.D. 0.33 N.D.
58 5mg/kg 28 N.D. N.D. N.D.
MUSCLE
100 5mg/kg 1 0.84 TRACE 0.15
101 5mg/kg 4 TRACE N.D. 0.08
99 5mg/kg 8 N.D. N.D. N.D.
32 5mg/kg 14 N.D. N.D. N.D.
47 5mg/kg 21 N.D. N.D. N.D.
58 5mg/kg 28 N.D. N.D. N.D.
PLASMA
100 5mg/kg 1 0.16 0.29 0.07
101 5mg/kg 4 0.03 N.D. N.D.
99 5mg/kg 8 N.D. N.D. N.D.
32 5mg/kg 14 N.D. N.D. N.D.
47 5mg/kg 21 N.D. N.D. N.D.
58 5mg/kg 28 N.D. N.D. N.D.
FBZ = Fenbendazole * = Mean values of two determinations
OFZ = Oxfendazole
OFZ.SO = Oxfendazole sulphone N.D. = Not detected
(< 0.05 Jig/g or yug/ml)
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FIGURE 7.2 Semi-logarithmic plot of liver residues of 
fenbendazole and oxfendazole after the 
administration of fenbendazole to sheep.
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Fenbendazole itself was not detectable in whole milk at any time 
after .treatment (Table 7.3)*
Oxfendazole was detectable in whole milk. Maximum concentrations 
were reached at twelve hours post-treatment in both animals
In one of the cows, oxfendazole was still detectable at 
thirty-six hours post-treatment (at a concentration of 0.07 yug/ml), 
but, at forty-eight hours post-treatment, concentrations had fallen 
below a detectable level.
In the other cow, oxfendazole was still detectable at sixty 
hours post-treatment (at a concentration of 0.03yug/ml), but, at 
seventy-two hours post-treatment, concentrations had fallen below a 
detectable level.
Oxfendazole sulphone was also detectable in whole milk. Maximum 
concentrations were reached at thirty-six hours post-treatment 
(0.09 yig/ml and 0.12 yag/ml).
In both cows, oxfendazole sulphone was still detectable at sixty 
hours post-treatment (only a trace amount was present in one of the 
cows, and a concentration of 0.02 yjg/ml in the other cow), but, at 
seventy-two hours post-treatment, concentrations had fallen below 
detectable levels.
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In the aqueous fraction of milk, fenbendazole itself was not 
detectable at any time after treatment (Table 7.4).
Oxfendazole was detectable in the aqueous fraction of milk. 
Maximum concentrations were reached at twelve hours post-treatment in 
both animals (0.12 yug/ml and 0.08 yag/ml).
In one of the cows, oxfendazole was still detectable at 
twenty-four hours post-treatment (at a concentration of 0.08yug/ml), 
but, at thirty-six hours post-treatment, concentrations had fallen 
below a detectable level.
In the other cow, oxfendazole was still detectable at thirty-six 
hours post-treatment (at a concentration of 0.04 yig/ml), but, at 
forty-eight hours post-treatment, concentrations had fallen below a 
detectable level.
Oxfendazole sulphone was also detectable in the aqueous fraction 
of milk. Maximum concentrations were reached at twelve hours 
post-treatment in both animals (0.01 jdg/ml in both animals).
In both cows, oxfendazole sulphone was still detectable at 
thirty-six hours post-treatment (again at a concentration of 
0.01 jjlg/ml in both animals), but, at forty-eight hours post-treatment, 
concentrations had fallen below detectable levels.
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TABLE 7.3 Milk residues (whole milk) of fenbendazole and
its metabolites in two cows
CONCENTRATION (yug/ml)
TIME(h) FENBENDAZOLE OXFENDAZOLE OXFENDAZOLE SULPHONE
0 0.00 0.00 0.00
0.00 0.00 0.00
12 N.D. 0.19 0.05
N.D. 0.32 0.05
24 N.D. 0.12 .0.07
N.D. 0.25 0.08
36 N.D. 0.07 0.09
N.D. 0.15 0.12
48 N.D. N.D. 0.06
N.D. 0.06 0.10
60 N.D. N.D. TRACE
N.D. 0.03 0.02
72 N.D. N.D. N.D.
N.D. N.D. N.D.
84 N.D. N.D. N.D.
N.D. N.D. N.D.
96 N.D. N.D. N.D.
N.D. N.D. N.D.
108 N.D. N.D. N.D.
N.D. N.D. N.D.
120 N.D. N.D. N.D.
N.D. N.D. N.D.
132 N.D. N.D. N.D.
N.D. N.D. N.D.
144 N.D. N.D. N.D.
N.D. N.D. N.D.




























TABLE 7*4 Milk residues (aqueous fraction) of fenbendazole
and its metabolites in two cows
CONCENTRATION tyig/ml)
TIME(h) FENBENDAZOLE OXFENDAZOLE OXFENDAZOLE SULPHONE
0 0.00 0.00 0.00
0.00 0.00 0.00
12 N.D. 0.08 0.01
N.D. 0.12 0.01
24 N.D. 0.06 0.01
N.D. 0.08 0.01
36 N.D. 0.04 0.01
N.D. N.D. 0.01
48 N.D. N.D. N.D.
N.D. N.D. N.D.
60 N.D. N.D. N.D.
N.D. N.D. N.D.
72 N.D. N.D. N.D.
N.D. N.D. N.D.
84 N.D. N.D. N.D.
N.D. N.D. N.D.
96 N.D. N.D. N.D.
N.D. N.D. N.D.
108 N.D. N.D. N.D.
N.D. N.D. N.D.
120 N.D. N.D. N.D.
N.D. N.D. N.D.
132 N.D. N.D. N.D.
N.D. N.D. N.D.
144 N.D. N.D. N.D.
N.D. N.D. N.D.
N.D. = not detected 
(< 0.5 yug/ml)




























After the administration of fenbendazole to sheep, residues were 
high and persisted for twenty-one days. The parent sulphide and its 
sulphoxide metabolite (oxfendazole) were found in liver in high 
concentrations. This was not unexpected since, after the 
administration of fenbendazole to sheep at a dose rate of 10 mg/kg, 
the parent drug and oxfendazole, along with oxfendazole sulphone, were 
found to be the major metabolites in plasma (Marriner and Bogan, 
1981b). Therefore, one would expect to find all three in tissues, as 
they circulate freely in plasma. However, muscle residues were very 
low. Total liver concentrations were thirty to forty times greater 
than total muscle and plasma concentrations. It is interesting to note 
that fenbendazole and its metabolites were undetectable in plasma at 
eight days post-treatment whereas in liver, residues were still 
detectable at twenty-one days post-treatment. It is a feature of all 
benzimidazoles studied, that they accumulate in the liver of sheep 
(i.e. albendazole, oxfendazole and thiabendazole) and are bound by 
some unknown mechanism.
One may have expected only one of the metabolites of 
fenbendazole to persist in tissues. However, fenbendazole and 
oxfendazole undergo a facile metabolic interconversion. Therefore, 
this may explain, in part, the persistence of both fenbendazole and 
oxfendazole in the liver of sheep. Furthermore, Marriner and Bogan 
(198la,b) reported that plasma concentrations of oxfendazole were
2.5 times higher after the administration of oxfendazole to sheep than 
they were after the administration of fenbendazole to sheep.
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Interestingly, liver residues of fenbendazole were very similar after 
both treatments to sheep. In addition, the insolubility of 
fenbendazole does not prevent high concentrations of oxfendazole 
occurring in the liver after the administration of fenbendazole to 
sheep, alghough higher concentrations of oxfendazole occur in the 
liver of sheep after the administration of oxfendazole (see 
Chapter 8). These data suggest that fenbendazole is absorbed after 
oral treatment, to an extent great enough that toxicity 
(e.g. teratogenicity) could occur at higher dose levels.
From all the residue data for fenbendazole in sheep, it was 
clear that if residues were present at twenty-eight days
residues were detectable at twenty-one days post-treatment. Therefore, 
the meat witholding time of fourteen days for sheep treated with 
fenbendazole may be inadequate, although an appraisal of toxicity, 
taking into account no-effect levels, acceptable daily intakes and 
safety factors would have to be undertaken to establish a realistic 
withdrawal time.
Residues of fenbendazole in sheep, cattle and pig tissues have 
been reported previously (Duwel, 1977). A fluorimetric method was used 
which unfortunately did not distinguish between the parent drug and 
its metabolites. However, Duwel (1977) found that after the 
administration of fenbendazole to sheep at a dose rate of 5 mg/kg 
(recommended dosage), residues persisted in liver. At fourteen days 
post-treatment, residues were detectable at a concentration of
post-treatment, they would be very low (less than However,
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0.20jig/g, but at twenty-one days post-treatment, residues were no 
longer detectable (less than 0.10 jig/g). In this experiment, residues 
were probably falsely low, because it has been found (see Chapter 9) 
that oxfendazole (the most persistent metabolite in liver after the 
administration of fenbendazole to sheep) is much less fluorescent than 
fenbendazole.
After the administration of fenbendazole to milking cows, the 
parent sulphide was not detectable in milk at any time. Oxfendazole 
and oxfendazole sulphone were detectable in milk after fenbendazole 
treatment. This was not surprising because oxfendazole and oxfendazole 
sulphone have been shown to be major metabolites in the plasma of 
cattle after fenbendazole treatment (Ngomuo et al., 1984). Residues in 
whole milk were higher than residues in the aqueous fraction of milk, 
which suggests that they are associated with both the lipid and the 
aqueous fractions of milk. The absence of the parent sulphide from 
milk may be due to the fact that after its administration to cattle, 
its concentration in plasma never exceeded 0.10 yug/ml (when 
fenbendazole was given at a dose rate of 7.5 mg/kg). Therefore, if it 
was present in milk, its concentration would be very low (probably 
below the limit of detection of of 0.05 yug/ml).
Residues of fenbendazole in cows’ milk have been reported 
previously (Duwel, 1977), although again, the method did not 
distinguish between the parent drug and its metabolites. Maximum 
concentrations of 0.30 |ig/ml were found at twenty-eight hours 
post-treatment, and at fifty-four hours post-treatment, concentrations 
had fallen below detectable levels (less than 0.10yug/ml).
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From all the residue data for fenbendazole in cows’ milk, it was 
clear that residues did not persist beyond sixty hours (if residues 
were present beyond this time, they would be very low: less than 
0.05 ^ ig/ml). Therefore, the milk witholding time of seventy-two hours 





Oxfendazole (methyl-5(6)-(phenylsulphinyl)- 2-benzimidazole 
carbamate) is a potent member of the benzimidazole group of 
anthelmintics. It has broad spectrum activity against 
gastro-intestinal roundworms (including inhibited larval stages), 
tapeworms and lungworms in many species (Averkin et al., 1975; Downey, 
1976; Chalmers, 1977; Lyons et al.. 1977).
The metabolism and pharmacokinetics of oxfendazole have been 
studied in various species (Prichard et al., 1978; Marriner and Bogan, 
1981a; Delatour et al., 1982a; Ngomuo et al., 1984). Prichard et al 
(1978) measured oxfendazole in sheep plasma using a previously 
developed radioimmunoassay procedure (Nerenberg et al., 1978). The
drawback to this method was that any oxfendazole measured may have 
been falsely high, as some cross-reactivity may have occurred with its 
metabolites.
After the administration of oxfendazole to sheep (Marriner and 
Bogan, 1981a), the parent oxfendazole was detected in plasma along 
with the sulphide metabolite (fenbendazole) and the sulphone 
metabolite (oxfendazole sulphone). Similarly, after the administration 
of oxfendazole to cattle (Ngomuo et al., 1984), the parent oxfendazole 
was detected in plasma along with fenbendazole and oxfendazole 
sulphone.
In the horse, oxfendazole, fenbendazole and oxfendazole sulphone 
were all detected in plasma after oxfendazole administration (Marriner 
and Bogan, 1985).
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A High Performance Liquid Chromatographic method has been
14
reported for the determination of C-labelled oxfendazole in cows’ 
milk (Tsina and Matin, 1981), but again, the method did not
distinguish between parent drug and metabolites.
It is important to distinguish between parent drug and
metabolites, especially in this case, where the parent compound is 
known to be teratogenic.
Oxfendazole has a wide margin of safety in all species of
domesticated animal. Its oral LD__ is greater than 6,400 mg/kg in rats
bU
and greater than 1,600 mg/kg in dogs (Averkin et al., 1975).
Oxfendazole has been extensively studied in the rat with regard 
to its potential teratogenicity. Delatour et al., (1984) conducted a 
study in which pregnant rats were treated from day eight to day 
fifteen of pregnancy, either with oxfendazole alone or oxfendazole 
combined with SKF-525A (an inhibitor of microsomal oxidation). They 
found that oxfendazole was teratogenic in the rat, but, oxfendazole 
combined with SKF-525A increased the embryotoxicity of oxfendazole. 
This was surprising since SKF-525A had an inhibitory effect upon 
gastro-intestinal absorption of oxfendazole (Delatour et al., 1984). 
Therefore, one would not expect increased embryotoxicity when blood 
concentrations of oxfendazole were decreased when it was administered 
in combination with SKF-525A.
From all this toxicological data, it is clear that in any
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residue studies involving oxfendazole, it is most important that the 
parent sulphoxide (oxfendazole) should be measured, as should the 
sulphide metabolite (fenbendazole), since none of the other
metabolites of oxfendazole have been found to be toxic. Although the
sulphide metabolite (fenbendazole) is not teratogenic, it is readily
interconvertible with oxfendazole (which is teratogenic), hence, it is 
important that both compounds are measured.
In all experiments, the animals were slaughtered at various 
times after the administration of oxfendazole. Liver, muscle, milk and 
plasma were analysed for residues of oxfendazole and its metabolites 
until they could be no longer detected (limits of detection 0.05yug/g 
for tissues and 0.05^ig/ml for milk and plasma). It was also assessed 
whether or not residues persisted beyond recommended withdrawal
periods (Table 8.1).
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TABLE 8.1 The meat and milk withholding times for











These studies involved the administration of oxfendazole to 
sheep by oral drench, at a dose rate of 5 mg/kg. They were slaughtered 
at 24 hours, 4, 8, 14, 21 and 28 days post-treatment. Samples of liver
o
and muscle were taken at slaughter and stored immediately at -20 C 
until assayed (as described in Chapter 3)» They were assayed in 
duplicate (Table 8.2). Blood samples were also taken at intervals 
throughout the experiment to assess the tissue/plasma ratio of
residues; plasma was removed after centrifugation and stored at -20°C 
until assayed (Table 8.2).
Cattle were also treated with oxfendazole, either orally by 
drench or intra-ruminally, both groups being given oxfendazole at a 
dose rate of 4.5 mg/kg. This experiment was part of a study conducted 
by Syntex (Bairden et al, 1983), to compare plasma concentrations 
reached after both treatments, and to correlate bioavailability with 
efficacy between the two routes of administration. The cattle treated 
orally were slaughtered at eight days post-treatment. The cattle 
treated intra-ruminally (by means of a Synanthic Intra-Ruminal 
Injector; Syntex Agribusiness, Palo Alto, California) were slaughtered 
at ten days post-treatment. Samples of liver and muscle were taken at
each slaughter and stored immediately at -20°C until assayed (as 
previously described). They were assayed in duplicate (Table 8.3) •
A third experiment was carried out in which milking cows were 
treatment with oxfendazole by oral drench, again at a dose rate of
4.5 mg/kg. Milk samples were taken before and at 12, 24, 36, 48, 60,
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72, 84, 96, 108, 120, 132 and 144 hours after treatment. Both whole 




After oxfendazole treatment of sheep (Table 8.2), oxfendazole 
itself was detectable in liver in high concentrations at one day 
post-treatment (a concentration of 4.96 ^ ig/g), although highest 
concentrations were detectable at four days post-treatment (a
concentration of 5.56 yug/g). Residues persisted, and at twenty-one 
days post-treatment oxfendazole was still detectable (at a
concentration of 0.12 yug/g), but, at twenty-eight days post-treatment, 
concentrations had fallen below a detectable level.
Fenbendazole was also detectable in liver in high concentrations 
at one day post-treatment (a concentration of 8.20 yug/g). Residues 
persisted, and at fourteen days post-treatment fenbendazole was still 
detectable (at a concentration of 0.86 yug/g), but, at twenty-one days 
post-treatment, concentrations had fallen below a detectable level.
Oxfendazole sulphone was detectable in liver at one day 
post-treatment (at a concentration of 0.70 yug/g), although highest 
concentrations were detectable at four days post-treatment (a
concentration of 0.87 yug/g). At eight days post-treatment oxfendazole 
sulphone was still detectable (at a concentration of 0.05 yug/g), but, 
at fourteen days post-treatment, concentrations had fallen below a 
detectable level.
A semi-logarithmic representation of the concentrations of 
oxfendazole and fenbendazole in liver versus time, after the 
administration of oxfendazole, was plotted (Figure 8.1). Linear 
regression analysis revealed straight lines for both compounds
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(R=0.986 for oxfendazole and 0.940 for fenbendazole), indicating 
first-order elimination.
In muscle, oxfendazole itself was not detectable at any time 
after treatment.
Fenbendazole was detectable in muscle at one day post-treatment 
(at a concentration of 0.94 yug/g), although in a much lower
concentration than was found in liver at the same time. It was still 
detectable at four days post-treatment (at a concentration of
0.33yig/g), but, at eight days post-treatment, concentrations had 
fallen below a detectable level.
Oxfendazole sulphone was also detectable in muscle at one day
post-treatment (at a concentration of 0.07 yug/g), although highest 
concentrations were detectable at four days post-treatment (a
concentration of 0.12yag/g). At eight days post-treatment, 
concentrations had fallen below a detectable level.
In plasma (Table 7.5), oxfendazole was detectable at one day
post-treatment (at a concentration of 0.43 yig/ml). It was still 
detectable at four days post-treatment (at a concentration of
0.04 yug/ml), but, at eight days post-treatment, concentrations had 
fallen below a detectable level.
Fenbendazole was also detectable in plasma at one day 
post-treatment (at a concentration of 0.11 yug/ml). Again, it was still
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detectable at four days post-treament (at a concentration of
0.02^ / 1111), but, at eight days post-treatment, concentrations had
fallen below a detectable level.
Oxfendazole sulphone was detectable in plasma at one day
post-treatment (at a concentration of 0.08 jig/ml). It was still 
detectable at four days post-treatment (at a concentration of
0.02 yag/ml), but, at eight days post-treatment, concentrations had























FIGURE 8.1 Semi-logarithmic plot of consentrations of oxfendazole 




.DAYS A F T E R  TREA TM ENT. _
TABLE 8.2 Liver, muscle and plasma residues of oxfendazole and
its metabolites in sheep
LIVER
Residues fyng/g wet wt) 
Animal No Dose Days After Treatment FBZ OFZ OFZ.SO
* * *
102 5mg/kg 1 8.20 4.96 0.70
99 5mg/kg 4 . 6.54 5.56 0.87
89 5mg/kg 8 1.04 1.54 0.05
83 5mg/kg 14 0.86 0.80 N.D.
116 5mg/kg 21 N.D. 0.12 N.D.
107 5mg/kg 28 N.D. N.D. N.D.
102 5mg/kg
MUSCLE
1 0.94 N.D. 0.07
99 5mg/kg 4 0.33 N.D. 0.12
89 5mg/kg 8 N.D. N.D. N.D.
83 5mg/kg 14 N.D. N.D. N.D.
116 5mg/kg 21 N.D. N.D. N.D.
107 5mg/kg 28 N.D. N.D. N.D.
PLASMA
Residues (yug/ml)
102 5mg/kg 1 0.11 0.43 0.08
99 5mg/kg 4 0.02 0.04 0.02
89 5mg/kg 8 N.D. N.D. N.D.
83 5mg/kg 14 N.D. N.D. N.D.
116 5mg/kg 21 N.D. N.D. N.D.
107 5mg/kg 28 N.D. N.D. N.D.
FBZ = Fenbendazole * = Mean values of two determinations
OFZ = Oxfendazole
OFZ.SO = Oxfendazole sulphone N.D. = Not detected
(<0.05 /ig/g or ^ ug/ml)
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After oxfendazole treatment of cattle (Table 8.3), oxfendazole 
itself was detectable in liver at eight days post-treatment (at a mean 
concentration of 0.56 yug/g) in all four calves. It was still
detectable at ten days post-treatment (at a mean concentration of 
0.20 yig/g), again in all four calves.
Fenbendazole was also detectable in liver at eight days
post-treatment (at a mean concentration of 0.89yug/g) in all four 
calves. Again, it was still detectable at ten days post-treatment (at 
a mean concentration of 0.37yug/g), again in all four calves.
Oxfendazole sulphone was detectable in liver at eight days 
post-treatment, although only in three of the four calves (in which 
only a trace amount was detectable). It was still detectable at ten 
days post-treatment, although only in one of the four calves (in which 
only a trace amount was detectable).
In muscle, oxfendazole, fenbendazole and oxfendazole sulphone
were not detectable at either eight or ten days post-treatment.
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TABLE 8.3 Liver residues of oxfendazole and its metabolites
in cattle
ORAL ADMINISTRATION
Residues fyug/g wet wt) 
Animal No Dose Days After Treatment FBZ OFZ OFZ.SO
# * *
17 4.5mg/kg 8 1.04 0.26 TRACE
20 4.5mg/kg 8 0.72 0.67 TRACE
33 4.5mg/kg 8 0.70 0.16 TRACE
56 4.5mg/kg 8 1.09 1.14 N.D.
Mean + S.E.M. 0.89+0.10 0.56+0.22
INTRA-RUMINAL ADMINISTRATION
17 4.5mg/kg 10 0.50 0.20 N.D.
20 4.5mg/kg 10 0.32 0.16 N.D.
33 4.5mg/kg 10 0.32 0.27 N.D.
56 4.5mg/kg 10 0.33 0.19 TRACE
Mean + S.E.M. 0.37+0.04 0.20+0.02
FBZ = Fenbendazole * = Mean values of two determinations
OFZ = Oxfendazole
OFZ.SO = Oxfendazole sulphone N.D. = Not detected ( < 0 . 0 5 g/g)
Muscle samples from each of these animals were taken at 
equivalent times to the liver samples. None of the samples had 
residues of FBZ, OFZ or OFZ.SO at the limit of detection (0.05/ig/g).
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After oxfendazole treatment, oxfendazole itself was detectable 
in whole milk (Table 8.4). In one of the cows, maximum concentrations 
were reached at twelve hours post-treatment (0.53 /ig/ml). At 
thirty-six hours post-treament it was still detectable (at a 
concentration of 0.l4^ig/ml), but, at forty-eight hours 
post-treatment, concentrations had fallen below a detectable level. In 
the other cow, maximum concentrations were reached at twenty-four 
hours post-treatment (0.36 yig/ml). At seventy-two hours post-treatment 
it was still detectable (at a concentration of 0.05 yug/ml), but, at 
eighty-four hours post-treatment, concentrations had fallen below a 
detectable level.
Oxfendazole sulphone was also detectable in whole milk. Maximum 
concentrations were reached at thirty-six hours post-treatment in both- 
animals (0.15^ig/ml and 0.16 ^ ig/ml). In one of the cows, it was still 
detectable at sixty hours post-treatment (at a concentration of 
0.02jjg/ml), but, at seventy-two hours post-treatment, concentrations 
had fallen below a detectable level. In the other cow, it was still 
detectable at eighty-four hours post-treatment (although only a trace 
amount was present), but, at ninety-six hours post-treatment, 
concentrations had fallen below a detectable level.
Fenbendazole was not detectable in whole milk at any time after 
oxfendazole treatment.
Oxfendazole was also detectable in the aqueous fraction of milk 
(Table 8.5). Maximum concentrations were reached at twelve hours
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post-treatment in both animals (0.12 yug/ml and 0.14 yjg/ml). In both 
cows, it was still detectable at twenty-fours post-treatment (in both 
cases at a concentration of 0.10 jig/ml), but, at thirty-six hours 
post-treatment, concentrations had fallen below detectable levels.
Oxfendazole sulphone was also detectable in the aqueous fracton 
of milk. In one of the cows, maximum concentrations were reached at 
twelve hours post-treatment (0.03 Jig/ml). At twenty-four hours 
post-treatment it was still detectable (at a concentration of 
0.01 jig/ml), but, at thirty-six hours post-treatment, concentrations 
had fallen below a detectable level. In the other cow, maximum 
concentrations were reached at twenty-four hours post-treatment 
(0.07 fig/ml), but, at thirty-six hours post-treatment, concentrations 
had again fallen below a detectable level.
Fenbendazole was not detectable in the aqueous fraction of milk 
at any time after oxfendazole treatment.
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TABLE 8.4 Milk residues (whole milk) of oxfendazole and
its metabolites in two cows
CONCENTRATION (yug/ml)
TIME(h) FENBENDAZOLE OXFENDAZOLE OXFENDAZOLE SULPHONE
0 0.00 0.00 0.00 A
0.00 0.00 0.00 B
12 N.D. 0.53 0.10 A
N.D. 0.34 0.08 B
24 N.D. 0.35 0.13 A
N.D. 0.36 0.11 B
36 N.D. 0.14 0.16 A
N.D. 0.19 0.15 B
48 N.D. N.D. 0.06 A
N.D. 0.10 0.15 B
60 N.D. N.D. 0.02 A
N.D. 0.02 0.10 B
72 N.D. N.D. N.D. A
N.D. 0.05 0.11 B
84 N.D. N.D. N.D. A
N.D. N.D. TRACE B
96 N.D. N.D. N.D. A
N.D. N.D. N.D. B
108 N.D. N.D. N.D. A
N.D. N.D. N.D. B
120 N.D. N.D. N.D. A
N.D. N.D. N.D. B
132 N.D. N.D. N.D. A
N.D. N.D. N.D. B
144 N.D. N.D. N.D. A
N.D. N.D. N.D. B
N.D. = not detected A = cow No.201 B = cow No.202
TABLE 8.5 Milk residues (aqueous fraction) of oxfendazole
and its metabolites in two cows
CONCENTRATION tyig/ml)
TIME(h) FENBENDAZOLE OXFENDAZOLE OXFENDAZOLE SULPHONE
0 0.00 0.00 0.00 A
0.00 0.00 0.00 B
12 N.D. 0.14 0.03 A
N.D. 0.12 0.03 B
24 N.D. 0.10 0.01 A
N.D. 0.10 0.07 B
36 N.D. N.D. N.D. A
N.D. N.D. N.D. B
48 N.D. N.D. N.D. A
N.D. N.D. N.D. B
60 N.D. N.D. N.D. A
N.D. N.D. N.D. B
72 N.D. N.D. N.D. A
N.D. N.D. N.D. B
84 N.D. N.D. N.D. A
N.D. N.D. N.D. B
96 N.D. N.D. N.D. A
N.D. N.D. N.D. B
108 N.D. N.D. N.D. A
N.D. N.D. N.D. B
120 N.D. N.D. N.D. A
N.D. N.D. N.D. B
132 N.D. N.D. N.D. A
N.D. N.D. N.D. B
144 N.D. N.D. N.D. A
N.D. N.D. N.D. B
N.D. = not detected A = cow No.201 B = cow No.202
DISCUSSION
After the administration of oxfendazole to sheep, residues were 
high and persisted for twenty-one days. The parent drug and its 
sulphide metabolite (fenbendazole) were found in liver in high 
concentrations. This was not unexpected since, after the 
administration of oxfendazole to sheep at a dose rate of 10 mg/kg, the 
parent sulphoxide and fenbendazole, along with oxfendazole sulphone, 
were found to be the major metabolites in plasma (Marriner and Bogan, 
1981a). Therefore, one would expect to find all three in tissues, as 
they circulate freely in plasma. However, muscle residues were very 
low. Total liver residues were around twenty times greater than total 
muscle and plasma residues. It is interesting to note that oxfendazole 
and its metabolites were undetectable in plasma at eight days 
post-treatment whereas in liver, residues were still detectable at 
twenty-one days post-treatment. As has been observed for albendazole, 
fenbendazole and thiabendazole, residues accumulate in the liver of 
sheep.
Residues of the parent drug and its sulphide metabolite both 
persisted. As has been explained previously (see Chapter 7)> 
oxfendazole and fenbendazole undergo a facile metabolic 
interconversion. Therefore, this may explain, in part, the persistence 
of both oxfendazole and fenbendazole in the liver of sheep.
An interesting finding was that after the administration of 
oxfendazole to sheep, residues of the parent compound, fenbendazole 
and oxfendazole sulphone were very similar at both one and four days 
post-treatment. This is not very surprising if one considers the
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residence time of oxfendazole and its metabolites in the 
gastro-intestinal tract of sheep and the plasma concentration versus 
time profiles for these compounds, as reported by Marriner and Bogan 
(1981a,b). After the oral administration of oxfendazole or 
fenbendazole to sheep, all three compounds were detectable in plasma 
for up to seven days, although the period from zero to four days 
accounted for the majority of the area under the plasma 
concentration/time curves for these compounds. From this data one may 
assume that absorption of these compounds from the gastro-intestinal 
tract is still occurring after four days, resulting in liver 
concentrations which are similar after both one and four days. This is 
strengthened by abomasal fluid concentrations of these compounds 
(Marriner and Bogan, 198la,b). For example, after the administration 
of fenbendazole to sheep, the mean concentration of oxfendazole in 
abomasal fluid was 0.64 yug/ml after twenty-four hours and it was very 
similar after four days (0.56 yug/ml).
From all the residue data for oxfendazole in sheep, it was clear 
that if residues were present at twenty-eight days post-treatment, 
they would be very low (less than 0.05 jig/g). However, residues were 
detectable at twenty-one days post-treatment. Therefore, the meat 
witholding time of fourteen days for sheep treated with oxfendazole 
may be inadequate, although an evaluation of toxicity, taking into 
account no-effect levels, acceptable daily intakes and safety factors 
should be carried out before making this judgement. For example, if 
one assumes that the ’’average" meal consists of 500g muscle, 100g fat, 
100g liver, 100g kidney and 500ml of milk, then one could estimate
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maximum daily intakes at certain withdrawal times. At fourteen days 
after the administration of oxfendazole to sheep, residues in liver 
only were detectable, and totalled 1.66 yig/g (equivalent to I66 i^ug 
which would be consumed). Assuming the average weight of a human to be 
70 kg, this would result in a maximum daily intake of approximately 
2 ^ jg/kg/day for a fourteen day withdrawal period. This amount would be 
very unlikely to pose any problem to humans as regards toxicity, 
although the assumption must be made that the susceptability of humans 
to the toxic effects of these compounds is similar to that of other 
animals which have been shown to be susceptible. Furthermore, 
comprehensive toxicity studies, including relay-bioavailability 
studies, would have to be carried out to determine ADIs, NELs and 
withdrawal periods accurately.
After the administration of oxfendazole to cattle, residues of 
oxfendazole, fenbendazole and oxfendazole sulphone were detectable in 
liver. This was not unexpected since, after the administration of 
oxfendazole to cattle at a dose rate of 4.5 mg/kg, oxfendazole, 
fenbendazole and oxfendazole sulphone were all detectable in plasma 
(Ngomuo et al., 1984). Unfortunately, this residue study was 
incomplete, as the tissues were obtained from cattle which had been 
used in an efficacy trial. However, from the amount of residues of 
oxfendazole (a mean concentration of 0.19 ^ g/g) and fenbendazole (a 
mean concentration of 0.37 /ig/g) still detectable in liver at ten days 
post-treatment, it is likely that residues would still be detectable 
in liver beyond the fourteen day meat witholding time for cattle 
treated with oxfendazole.
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After the administration of oxfendazole to milking cows, the 
parent drug and oxfendazole sulphone were detectable in milk. This was 
not surprising because oxfendazole and oxfendazole sulphone are found 
in the plasma of cattle after oxfendazole treatment (Ngomuo et_al., 
1984). Fenbendazole was not detectable in milk at any time after 
oxfendazole treatment. The absence of fenbendazole from milk may be 
due to the fact that after the administration of oxfendazole to cattle 
at a dose rate of 4.5 mg/kg, the concentration of fenbendazole in 
plasma was sufficiently low that if it were present in milk, its
concentration would be very low (probably below the limit of detection
of 0.05 jig/ml).
Residues of oxfendazole and oxfendazole sulphone in whole milk 
were higher than residues in the aqueous fraction of milk, which 
suggests that they are associated with both the lipid and the aqueous 
fractions of milk (which was the case with milk residues after 
fenbendazole treatment). Residues in whole milk were of the order of 
four times greater than those in the aqueous fraction, therefore, one 
could assume that the majority of residues were associted with the fat 
in milk. One may speculate that fat residues (although not determined) 
would be very similar to those in the fat of milk, assuming uniform 
distribution of these compounds into all types of fat.
From all the residue data for oxfendazole in cows’ milk, it was
clear that residues did not persist beyond eighty-four hours (if 
residues were present beyond this time, they would be very low: less
than milk witholding time of one hundred
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and twenty hours for cattle treated with oxfendazole would seem to be 
adequate.
Overall, a complete evaluation of residues should include kidney 
and fat, which were not determined in these studies. If these tissues 
were included, a more complete picture of the residue profiles could 
be drawn, allowing more accurate estimations of acceptable daily 




Thiabendazole (2-(4,-thiazolyl)-benzimidazole) is a member of the 
benzimidazole group of anthelmintics with broad spectrum activity 
against gastro-intestinal roundworms and tapeworms in sheep, cattle and 
many other species (Brown et al., 1961; Cuckler, 1961). It is also
effective against trichinosis in rats and mice (Campbell, 1961) and in
swine (Campbell and Cuckler, 1962). It has been shown to be effective 
against inhibited Ostertagia larvae in cattle (Prichard et al., 1978), 
but only if drug concentrations were maintained by continuous infusion 
or frequently repeated administration. Thiabendazole had previously 
been shown to be ineffective (at a single dose) against inhibited 
larvae (Armour, 1969; Armour et al., 1975; Anderson, 1977).
The metabolism and pharmacokinetics of thiabendazole have been 
studied in sheep (Tocco et al., 1964) and in cattle, goats and pigs
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(Tocco et al., 1965) using C-labelled thiabendazole. Both 
thiabendazole and 5-hydroxythiabendazole were detected in urine, but 
plasma concentrations were not reported. It is known, however, that 
5-hydroxythiabendazole is conjugated in the liver, both glucuronide and 
sulphate conjugates being found (Tocco et al., 1964). In cattle, 
thiabendazole was administered orally, at dose rates of 50 mg/kg and 
200 mg/kg (Tocco et al., 1965). Unchanged thiabendazole was not
detectable in plasma at any time after treatment (even at a dose rate 
of 200 mg/kg). Maximum plasma concentrations of 5-hydroxythiabendazole 
occurred between four and seven hours after treatment. Thereafter,
concentrations of 5-hydroxythiabendazole fell rapidly and were 
virtually undetectable after twenty-four hours (50 mg/kg) and
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forty-eight hours (200 mg/kg). Also, unchanged thiabendazole was not 
detected in urine at any time after treatment.
Although 5-hydroxythiabendazole is the major metabolite of 
thiabendazole in sheep urine and plasma (see later) and in cattle 
plasma, it is considered to be anthelmintically inactive (Stone et al., 
1965). Hence, anthelmintic activity may be greater in sheep than in 
cattle (since thiabendazole is more rapidly converted to 
5-hydroxythiabendazole in cattle).
Several High Performance Liquid Chromatographic methods for the 
determination of thiabendazole have been reported (Maeda and Tsuji, 
1976; Farrow et al., 1977; Isshiki et al., 1980; Tafuri et al., 1981). 
However, for two reasons, none of these methods are suitable for 
measuring thiabendazole in plasma. Firstly, they are not designed for 
the determination of thiabendazole in plasma. Secondly, they do not 
distinguish between thiabendazole and its major metabolite 
(5-hydroxythiabendazole). Measurement of 5-hydroxythiabendazole is 
important as it has been observed that the accumulation of 
5-hydroxythiabendazole was linked with hepatotoxicity in a human 
patient who was unable to eliminate it because of impaired renal 
function (Schumaker et al., 1978).
Acute toxicity studies with thiabendazole have demonstrated (like 
all the other benzimidazoles) that it is well tolerated in the host 
animal, although the literature is lacking in detailed information 
regarding the toxicity of thiabendazole. However, in the rat,
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thiabendazole appears to be non-teratogenic (Tanaka et al.t 1982), but 
minor abnormalities (retardation of ossification of the sternum) were 
suggested at a dose rate of 500 mg/kg (Khera et al., 1979). In the 
mouse, various abnormalities have been described for thiabendazole at 
extremely high dose rates of 700 mg/kg to 2400 mg/kg (Kubo et al., 
1982; Ogata et al., 1982 and 1984).
In the following experiments with thiabendazole, both the parent 
compound and 5-hydroxythiabendazole were measured.
In all experiments, the animals were slaughtered at various times 
after the administration of thiabendazole. Liver, muscle, milk and 
plasma were analysed for residues of thiabendazole and 
5-hydroxythiabendazole until they could be no longer detected (limits 
of detection 0.05 ^ Jg/g for tissues and 0.05^ig/ml for milk and plasma).
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RESIDUES OF THIABENDAZOLE AND 5-HYDROXYTHIABENDAZOLE IN THE TISSUES OF
SHEEP
In this experiment, four sheep were given thiabendazole orally, 
at a dose rate of 44 mg/kg (recommended dosage) (Table 9.1). They were 
slaughtered at 1, 2, 3 and 4 days post-treatment.
Samples of liver and muscle were taken at slaughter and stored 
immediately at -20°C until assayed (as described in Chapter 3).
All liver and muscle samples were assayed in duplicate 
(Tables 9.2 and 9.3).
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TABLE 9.1 Weights, dose volumes and dosages for the four sheep used in the 
thiabendazole residue study






91 74 18.5 3256 44
92 61 15.2 2684 44
93 64 16.0 2816 44
94 69 17.2 3036 44
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TABLE 9.2 Liver residues of thiabendazole and 5-hydroxythiabendazole in































* = Mean value of two determinations 
N.D. = not detected
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TABLE 9.3 Muscle residues of thiabendazole and 5-hydroxythiabendazole in




























* Mean value of two determinations 
N.D. = not detected
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After thiabendazole treatment, thiabendazole itself was 
detectable in liver at one day post-treatment (at a concentration of 
2.24 yug/g). It was still detectable at three days post-treatment (at a 
concentration of 0.80 yug/g), but, at four days post-treatment, 
concentrations had fallen below a detectable level.
5-Hydroxythiabendazole was also detectable in liver at one day 
post-treatment (at a concentration of 2.44 yug/g), but, at two days 
post-treatment, concentrations had fallen below a detectable level.
In muscle, thiabendazole was detectable at one day post-treatment 
(at a concentration of 0.34 yug/g), but, at two days post-treatment, 
concentrations had fallen below a detectable level.
5-Hydroxythiabendazole was also detectable in muscle at one day 
post-treatment (at a concentration of 0.24yug/g), but, at two days 
post-treatment, concentrations had fallen below a detectable level.
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THIABENDAZOLE AND 5-HYDROXYTHIABENDAZOLE IN THE PLASMA OF SHEEP
In the course of the investigation into the residues of 
benzimidazole anthelmintics in the tissues of sheep, it was found that 
the fate of thiabendazole in the blood of sheep is different from that 
of cattle and goats, the two species in which blood concentrations of 
thiabendazole and its principal metabolite 5-hydroxythiabendazole have 
been measured separately (Tocco et al., 1965). Tocco et al., (1964) 
have reported on total thiabendazole and metabolite concentrations
14 35using C and J S-labelled thiabendazole in sheep.
In this investigation, six Finn-Dorset X adult lambs on a hay and 
concentrates diet were given thiabendazole orally, at a dose rate of 
44 mg/kg (recommended dosage). Blood samples were collected by 
venepuncture before and at 2, 4, 6, 8, 12, 24, 36, 48 and 72 hours
post-treatment; plasma was removed by centrifugation and stored at
-20°C until assayed (as described in Chapter 3). All samples were 
assayed for thiabendazole and 5-hydroxythiabendazole (a gift from 
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After thiabendazole treatment, thiabendazole itself was 
detectable in plasma. Maximum concentrations were reached between two 
and four hours (a mean maximum concentration of 2.16 p g/ml) 
post-treatment. At twenty-four hours post-treatment, thiabendazole was 
still detectable in plasma (at a mean concentration of 0.02 jug/ml), but 
at thirty-six hours post-treatment, concentrations had fallen below a 
detectable level.
5-hydroxythiabendazole was also detectable in plasma after 
thiabendazole treatment. Maximum concentrations were reached at six 
hours post-treatment (a mean maximum concentration of 0.18 ^ ig/ml). At 
twelve hours post-treatment, 5-hydroxythiabendazole was still 
detectable in plasma (at a mean concentration of 0.13 ^ ig.ml), but at 
twenty-four hours post-treatment, concentrations had fallen below a 
detectable level.
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RESIDUES OF THIABENDAZOLE AND 5-HYDROXYTHIABENDAZOLE IN COWS* MILK
In this experiment, two Friesian cows in mid-lactation were given 
thiabendazole orally, at a dose rate of 66 mg/kg (recommended dosage) 
(Table 9.5). Their weights were estimated to be 550 kg each.
The cows were milked twice daily (approximately every 12 hours), 
thiabendazole being administered immediately after the afternoon 
milking.
Samples were taken before and at 12, 24, 36, 48, 60, 72, 84, 96, 
108, 120, 132 and 144 hours after treatment.
The samples were stored immediately at -20°C until assayed (as 
described in Chapter 3).
All milk samples were analysed in two ways:-
1) Whole milk was analysed.
2) Milk was separated into aqueous phase (whey) and lipid phase 
(curds). The aqueous phase was then analysed for residues.
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TABLE 9.5 Weights, dose volumes and dosages for the two cows used 
in the thiabendazole milk residue study
COW NO. WT. (kg) VOL. SUSPENSION TOTAL DOSE DOSE RATE
17-6% w/v (ml) (mg) (mg/kg)
207 550 206 36300 66
208 550 206 36300 66
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Neither thiabendazole nor 5-hydroxythiabendazole were detectable 
in whole milk at any time after treatment (limit of detection of 
0.5 jug/ml for both compounds).
Similarly, neither thiabendazole nor 5-hyxroxythiabendazole were 
detectable in the aqueous fraction of milk at any time after treatment 
(limit of detection of 0.5 Aig/ml for both compounds).
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DISCUSSION
After the administration of thiabendazole to sheep, residues of 
the parent drug and its metabolite 5-hydroxythiabendazole were 
detectable in tissues. The most surprising finding was that 
thiabendazole itself was detectable in liver three days after its 
administration to sheep. This result was unexpected because 
thiabendazole was not detectable in plasma after twenty-four hours. 
This situation was similar to that which occurred with febantel, 
fenbendazole and oxfendazole. That is, tissue residues are higher and 
persist much longer than plasma residues.
In contrast to cattle and goats, where parent thiabendazole is 
not detectable in plasma, thiabendazole was present in the plasma of 
sheep for twenty-four hours after dosing and at higher concentrations 
than the 5-hydroxymetabolite.
These findings are consistent with those of Tocco et al., (1964 
and 1965), who showed that metabolism and excretion of thiabendazole is 
more extensive in cattle than in sheep. They found that 94% of total 
radioactivity in lambs was accounted for as 5-hydroxythiabendazole or 
its conjugates, with 2% being excreted unchanged (the remaining h% was 
unidentified), whereas in a calf no unchanged thiabendazole was 
detectable in the urine.
This result may also have implications for the efficacy of 
thiabendazole in sheep. It is considered that 5-hydroxythiabendazole is
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not anthelraintically active (Stone et_al., 1965). Hence, anthelmintic 
activity in the systemic compartment may be greater in sheep than in 
cattle. For example, thiabendazole is considered to be without effect 
against lungworm (Dictyocaulus viviparus) in cattle, whereas Gibbs and 
Pullin (1963) found useful activity against lungworm (Dictyocaulus 
filaria) in sheep. Thiabendazole also shows activity against arrested 
larval stages of gastro-intestinal nematodes in sheep, but not in 
cattle, although this may also be a consequence of access of 
anthelmintic to the larvae in sheep being easier than in cattle because 
of the thinner gastro-intestinal mucosa (Armour, 1983).
The anthelmintic activity of thiabendazole is probably limited by 
two factors. Firstly, it is the most soluble of the benzimidazoles 
(Ngomuo, 1983) and, secondly, it is rapidly metabolized. For both these 
reasons, the duration of exposure of the parasites to the drug is short 
compared to the other benzimidazoles. Prichard et al., (1978) have 
shown that extending the duration of exposure of parasites to 
thiabendazole can produce activity even against inhibited larvae in 
cattle.
The concentrations of thiabendazole found in these sheep (mean 
maximum concentration 2.l6^ig/ml at this dose of 44 mg/kg) are low 
compared to those of the anthelmintically active metabolite 
(albendazole sulphoxide) of albendazole in sheep (mean maximum 
concentration 3.2 ^ ig/ml at a dose of 10 mg/kg) (Marriner and Bogan, 
1980). Since Tocco et al., (1964) found 75% of an administered dose of 
14 35
C and S-labelled thiabendazole to be excreted in the urine of lambs
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in forty-eight hours, these low plasma concentrations of thiabendazole 
and 5-hydroxythiabendazole are a consequence of rapid excretion of 
thiabendazole and 5-hydroxythiabendazole, rather than poor absorption.
After the administration of thiabendazole to milking cows, it was 
found that neither thiabendazole nor 5-hydroxythiabendazole were 
detectable in milk at any time. This was not surprising because the 
parent drug was not detectable in plasma after its administration to 
cattle (Tocco et al., 1965) and also the metabolite 
5-hydroxythiabendazole was rapidly excreted because of its high aqueous 
solubility.
From all the residue data for thiabendazole in sheep, it was 
clear that if residues were present at four days post-treatment, they 
would be very low (less than 0.05 yug/g). However, residues were 
detectable for three days. Therefore, the fact that in sheep treated 
with thiabendazole there is no meat witholding time should be 
investigated further. The zero milk witholding time for cattle treated 
with thiabendazole seems to be adequate.
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CHAPTER 10
FLUORIMETRIC DETECTION OF BENZIMIDAZOLES
High performance liquid chromatography with ultra-violet 
detection has been used over the past few years to estimate 
concentrations of benzimidazoles and their metabolites in plasma and, 
more recently, in tissues.
Ultra-violet detection allows detection of most benzimidazoles 
and their metabolites to concentrations of 0.05 fig/ml ip-g/g for 
tissues) or less.
During the course of tissue residue studies, a fluorimetric 
detector (Perkin-Elmer LS-4 Fluorescence Spectrometer) became available 
and it was decided that the possibility of increasing the sensitivity 
and specificity of the methods for the determination of benzimidazoles 
and their metabolites in plasma and tissues should be investigated.
DETECTION OF BENZIMIDAZOLE RESIDUES USING FLUORIMETRY
Without change to the extraction methods or HPLC conditions, 
ultra-violet detection was compared with fluorimetric detection. For 
some of the drugs and metabolites there was a marked increase in 
sensitivity up to fifty times, using fluorimetric detection. 
Unfortunately this increase in sensitivity did not apply to all the 
drugs and metabolites, but nevertheless, in no case was fluorimetric 
detection less sensitive than ultra-violet and this method of detection 
could be adopted as the routine. In some cases, the limit of detection 
was improved to 0.0005 jug/g tissue, such as for albendazole sulphone.
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Fluorimetry offers much improved limits of detection for 
albendazole and thiabendazole and their metabolites and little 
improvement for fenbendazole, oxfendazole and febantel. However, 
although the limits of detection for these are not improved, the 
specificity of the detection methods appears to be better using 
fluorimetry, such that the risk of "false positives" is much reduced. A 
possible use of fluorimetry may be as a further confirmatory test for 
any residues detected by U.V. spectrometry. The limits of detection 
using fluorescence and the limits of detection using ultra-violet are 
shown in Table 10.1.
Typical chromatograms obtained using the method applied to liver 
samples from sheep treated with albendazole and thiabendazole using the 
two methods of detection are shown in Figures 10.1-10.4.
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Injection volumes and other conditions were the same for both 
detection systems. The U.V. detection system was operated at the limit 
for a stable baseline of 0.05 AUFS. The fluorimeter (Perkin-Elmer LS-4) 
could be operated at a scale of X5.
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FIGURE 10.1 Ultra-violet detection of thiabendazole.
A = Thiabendazole (20pg/ml standard in methanol).
B = Liver sample from a sheep killed four days
after the administration of thiabendazole (44mg/kg).




A = Thiabendazole (20pg/ml standard in methanol)
B = Liver sample from a sheep killed four days after 
the administration of thiabendazole (44mg/kg).
Fixed scale = 2.5.
FIGURE 10.3 Ultra-violet detection of albendazole.
A = Liver sample from a sheep killed one day after 
the administration of albendazole (5mg/kg).
B = Albendazole (2CJug/ml standard in methanol).
FIGURE 10.4 Fluorimetric detection of albendazole.
B
A = Liver samples (diluted x 5) from a sheep killed one 
day after the administration of albendazole (5mg/kg).




Samples of liver obtained from 25 calves, 25 cattle and 50 sheep 
post mortem from abattoirs distributed throughout the U.K. and listed 
in Tables 10.2-10.4 were analysed by the standard method using both 
U.V. and fluorimetric methods of detection. Thus, for all residues 
being sought the detection limit was 0.05 jig/g or better.
In no sample of liver were any benzimidazole or metabolite 
residues found. No spurious "peaks” or "false positives" were found in 
any sample.
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TABLE 10.2 Details of randomly selected abattoir liver samples from 
cattle.
SAMPLE No. SPECIES SEX ANIMAL AGE (Yrs) ABBATOIR AREA DATE
CA84/174 B F 5 W. ENGLAND 30/05/84
CA84/18 2 B M(1J 6 S.W. ENGLAND 7/06/84
CA84/185 B F - N.W. ENGLAND 13/06/84
CA84/18 6 B F 2 S.W. ENGLAND 18/05/84
CA84/191 B F 3+ S.W. ENGLAND 21/06/84
CA84/196 B F 2. W. SCOTLAND 14/06/84
CA84/199 B M 2 W. SCOTLAND 14/06/84
CA84/201 B M 1+ S.E. ENGLAND 22/06/84
CA84/202 B F 5 N.W. ENGLAND 21/06/84
CA84/208 B - ■- N.W. ENGLAND 27/06/84
CA84/217 B M (1) 2 W. ENGLAND 28/06/84
CA84/220 B F 2 E. ENGLAND 13/07/84
CA84/224 B F 2 S. ENGLAND 10/07/84
CA84/232 B M 1+ S.E. ENGLAND 06/07/84
CA84/233 B M 2 S.E. ENGLAND 12/07/84
CA84/237 B M 2 E. SCOTLAND 23/07/84
CA84/238 B M 1 S.W. ENGLAND 17/07/84
CA84/276 B M 1+ W. SCOTLAND 28/03/84
GA8 4/3 03 B F - N.W. ENGLAND 14/09/84
CA84/309 B M ' 2 S.W. ENGLAND 18/09/84
CA84/315 B F 1+ N.E.SCOTLAND 19/09/34
CA84/318 B F- 1+ W. SCOTLAND 19/0 9/8 4
CA84/335 B F 5 S.W. ENGLAND 27/09/34
CA84/341 3 F - S.W. ENGLAND 02/10/84
CA84/361 B F • 1+ S.W. ENGLAND 0 5/11/8 4
KEY B = BOVINE F1 = FEMALE M = MALE M (1) = BULL
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TABLE 10.3 Detail of randomly selected abattoir liver
samples from calves.
SAMPLE Mo . SPECIES SEX ANIMAL AGE (Wks) ABBATOIR AREA DATE
CV84/100 ' B MCD 1 S. ENGLAND 01/05/84
CV84/105 B M (1) 4 C. ENGLAND 04/05/84
CV84/110 B M - S.W. ENGLAND 26/05/84
CV84/113. B M 1 S.W. ENGLAND 23/05/84
CV84/123 B M 13 S.W. ENGLAND 12/06/84
CV84/132 B - 20 S. ENGLAND 13/06/84
CV84/134 B M 1- W. SCOTLAND 28/06/84
CV84/135 B M(l) - S.W. ENGLAND 2 9/06/84
CV84/I37 B M 13 S.W. ENGLAND 17/07/84
CV84/149 B MCI) 1 S. ENGLAND 18/07/84
CV8 4/15.0 B M 3 C. ENGLAND 26/07/84
CV84/151 B M(l) - S.W. ENGLAND 24/07/84
CV84/156 B M 2 N.W. ENGLAND 30/07/84
CV84/159 B M 12 N.E. ENGLAND 16/07/84
CV84/160 B M - S.E. ENGLAND 25/07/84
CV84/168 B M 36 W. SCOTLAND 23/08/84
CV84/171 B F 1 WALES 25/07/84
CV84/174 B M 1 S.W. ENGLAND 12/09/84
CV84/181 B M 1 S.W. ENGLAND 19/09/84
CV84/184 B M(l) 1 C. ENGLAND 03/10/84
CV84/185 B M(l) 1 S.E. ENGLAND 03/10/84
CV84/195 B M ‘ 3 S.W. ENGLAND 22/10/34
CV84/201 B - - S.W. ENGLAND 11/10/84
CV84/202 B M 1 W. SCOTLAND 19/10/84
CV84/206 B M ' 1 N. ENGLAND 31/10/84
KEY•B = BOVINE F =. FEMALE M == MALE M (1) = BULL
TABLE 10.4 Details of randomly selected abattoir liver
samples from sheep.
SAMPLE No. SPECIES SEX AMIMAL AGE (Mth) ABBATOIR AREA DATE
S84/78 0 F 12 ’ S. ENGLAND 04/04/84
S84/88 0 F . - S.W. ENGLAND 10/04/84
S84/103 0 F 12 . N.W. ENGLAND 26/03/84
S84/108 0 F 4 S. ENGLAND 15/05/84
S84/124 0 M 4 N.E.SCOTLAND 17/05/84
S84/126 0 F 12 W. ENGLAND 30/05/84
S84/144• 0 F 5 S.W. ENGLAND 07/06/84
S84/152 0 M - N.W. ENGLAND 20/06/84
S84/160 0 M 4 C. ENGLAND 19/06/84
S84/167 0 M - WALES ’ 06/07/84
S84/177 0 F N. ENGLAND 20/07/84
S84/181 0 M - S.W. ENGLAND 17/07/84
S84/184 0 F 8 N.E. ENGLAND 17/07/84
S84/187 0 F 6 S.W. ENGLAND 30/07/84
S84/188 0 F 6 W. SCOTLAND 24/07/84
S84/192 0 M - C. ENGLAND 08/08/84
S84/203 0 M - WALES 17/08/84
S84/208 0 F 7 E. ENGLAND 2 9/0 8/84
S84/215 0 M 5 N.W. ENGLAND 11/09/84
S84/225 0 F 10 N.W. ENGLAND 11/08/84
S84/233 0 F 6 C. ENGLAND 19/09/84
S84/241 0 M 5 N.W. ENGLAND 17/09/84
S84/262 0 f ' 11 N.W. ENGLAND 18/10/84
S84/263 0 F 10 N.E. ENGLAND 15/10/84
S84/266 0 F - S.E. ENGLAND 01/11/84
S84/271 0 M 8 E. SCOTLAND 12/11/84
S84/27 2 0 M 12 N.E. ENGLAND 20/11/84
S84/275 0 - 8 S. ENGLAND 22/11/84
S84/278 0 M 10 S. ENGLAND 15/11/84
S84/281 0 F 8 N.E.SCOTLAND 13/11/84
S84/284 0 M 8 WALES 27/11/84
S84/285 0 F - WALES 26/11/84
S84/287 0 M 8 W. ENGLAND 07/11/84
S84/290 0 M 18 N.W. ENGLAND 26/10/84
S84/306 0 F 11 N.W. ENGLAND 28/11/84
S84/308 0 M 8 WALES 24/10/84
S85/34 0 F 12 C . ENGLAND 12/02/85
S85/36 0 M 12 N.W. ENGLAND 13/02/85
S85/46 0 M 11 WALES 08/03/85
S85/47 • 0 F ’ 12 WALES 12/03/85
S85/49 0 M 9 W. ENGLAND 14/03/85
S85/50 0 M 12 E. ENGLAND 19/03/85
S85/55 0 F 8 S.W. ENGLAND 21/03/65
S85/63 0 M 72 E. ENGLAND 15 '02/85
S85/70 0 M - N.E.SCOTLAND 18 '04/85
S85/71 0 F - E. ENGLAND 15, 04/85
S85/72 0 M 12 * N. SCOTLAND 23/04/85
S85/75 0 F 72 W. ENGLAND 09/04/85
S85/76 0 M 15 W. SCOTLAND 18/04/85
S85/80 0 F - N.W. ENGLAND 18/04/85




The feature common to all the benzimidazoles studied with respect 
to tissue residues was that the concentrations in liver were 
considerably greater than those in muscle, kidney, plasma and milk. The 
limits of detection were similar for all tissues and plasma, and the 
residues in liver were detectable for longer periods than those of the 
other tissues and plasma.
In general, the temporal pattern of residues accorded with the 
known plasma pharmocokinetics of each of the compounds. That is, there 
was a direct correlation between the residence time of these compounds 
in plasma and their persistence in tissues, in that those 
benzimidazoles which did not persist in plasma did not persist in 
tissues, and those which did persist in plasma did persist in tissues. 
Thus, the order of diminution of residues was: thiabendazole followed
by albendazole, followed by febantel, fenbendazole and oxfendazole.
Liver residues of febantel, fenbendazole and oxfendazole all 
followed the same pattern. After the administration of these three 
compounds, oxfendazole was detectable in liver in greater 
concentrations than any of the other metabolities. It has been 
demonstrated previously that oxfendazole is the most important 
metabolite in the plasma of sheep after the administration of febantel 
(Delatour et al., 1985a), fenbendazole (Marriner and Bogan, 1981b) and 
oxfendazole itself (Marriner and Bogen, 1981a). Therefore, it is clear 
that the similar residue profiles after the administration of these 
three anthelmintics was due to the contribution of high concentrations 
of oxfendazole in the liver in each case. Oxfendazole was also the
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longest residing metabolite in the liver of sheep after all three 
treatments, which may be due to the fact that it is intermediate 
between fenbendazole and oxfendazole sulphone after the administration 
of all three compounds, such that it can be converted to either one, 
with a resultant decreased rate of elimination.
It appears that benzimidazoles bind to liver tissue, although the 
mechanism and extent of binding have not been investigated. It has been 
reported (Delatour et al., 1983) that albndazole binds to liver 
protein, although the mechanism of binding is unknown. This may 
explain, in part, the high residues found in liver after the 
administration of benzimidazoles to sheep, although it is more likely 
that these high residues are a result of entero-hepatic circulation of 
benzimidazoles. After oral administration, high benzimidazole 
concentrations were detectable in sheep abomasal fluid for up to six 
days (Marriner and bogan 1981a and 1981b). This was attributed to 
passive diffusion of drug from the systemic compartment to the 
abomasum. Therefore, entero-hepatic circulation and passive diffusion 
of benzimidazoles into the abomasum (which would allow drug to be 
re-absorbed) may explain, in part, the high residues found in liver and 
also the persistence of these residues long after concentrations in 
plasma had fallen below detectable levels. It may also explain the 
finding that liver residues were much higher than muscle and kidney 
residues after the administration of benzimidazoles to sheep. The 
greatest hazard to the consumer would arise, therefore, from the 
consumption of liver, and any screening programme for the examination 
of meat from animals suspected of being treated with a benzimidazole
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close to slaughter, should concentrate on the analysis of liver for 
residues.
Compared to sheep, residues in cattle tissues were very much 
lower, although only albendazole, albendazole sulphoxide and
oxfendazole were used to study benzimidazole residues in the tissues of 
cattle. It is known that the capacity for the metabolism of
benzimidazoles is greater in cattle than in sheep. Pharmacokinetic 
studies of oxfendazole in sheep (Marriner and Bogan, 1981a) and cattle 
(Ngomuo et al., 1984) have shown tha-t plasma concentrations of 
anthelmintically active metabolites were less in cattle than in sheep 
at the same dose rate. Therefore, the finding that tissue residues in 
cattle were very much lower than tissue residues in sheep did not come 
as a great surprise. It is interesting that the teratogenic effects of 
benzimidazoles in cattle are considerably lower than those in sheep. 
For example, albendazole is teratogenic in sheep at a dose rate of 
11 mg/kg, whereas it is not teratogenic in cattle at a dose rate of 
25 mg/kg.
It is interesting to note that in sheep, liver residues of 
febantel, fenbendazole, oxfendazole and thiabendazole all were 
detectable beyond their recommended withdrawal periods. In particular, 
thiabendazole (which has a nil withdrawal time in cattle and sheep) was 
still detectable in liver three days after its administration to sheep. 
There have been no reports of tissue residues of thiabendazole, and 
therefore, one can only assume that it was given a nil withdrawal time
because, either residues have not been found or, if residues were
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found, they were not considered a problem as regards toxicity to 
humans. More likely, however, is that residues of thiabendazole .have 
not been determined because it has a licence of right. It is also 
interesting to note that febantel has only an eight day withdrawal time 
in cattle and sheep, despite having similar kinetics to fenbendazole 
and oxfendazole in sheep (both these anthelmintics have fourteen day 
withdrawal periods in cattle and sheep). Therefore, if all three of 
these anthelmintics have similar pharmacokinetics, and their residue 
profiles are similar (both qualitatively and quantitatively), then they 
should all have the same withdrawal period. Although residues of 
fenbendazole and oxfendazole were present beyond their recommended 
withdrawal times, these residues may not be considered a problem, as 
regards toxicity to the consumer. For example, these residues were only 
detectable in liver at twenty-one days, and assuming that the average 
human diet does not consist of large quantities of liver, it is 
unlikely that exposure to these residues would be very high. In 
addition, if large quantities of liver were consumed, it is again 
unlikely that these residues would be absorbed to any significant 
extent, although relay toxicity studies would have to be carried out in 
other monogastric animals before one could be certain of this.
In milk, residues of all the drugs studied were low compared to 
tissue residues. None of these drugs were detectable in milk beyond 
recommended milk withholding times. The absence of thiabendazole 
residues from cows1 milk was not surprising, since thiabendazole has a 
much higher aqueous solubility than any of the other drugs studied, and 
as a result it is more rapidly absorbed and eliminated than any of the
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others. However, uniquely among the benzimidazoles, thiabendazole has 
fungicidal properties, which is likely to cause problems in the 
production of cheese and yoghurt from sheep’s milk (which is more 
likely to contain residues after thiabendazole treatment).
It is interesting to compare milk residues of oxfendazole after 
the administration of fenbendazole and after the administration of 
oxfendazole itself. Residues persisted longer after the administration 
of oxfendazole than they did after the administration of fenbendazole. 
This is probably due to the fact that higher concentrations of 
oxfendazole are achieved in the plasma of cattle after the 
administration of oxfendazole than are achieved after the 
administration of fenbendazole (Ngomuo et al., 1984). Therefore, if 
fenbendazole is not detectable in milk, it is obvious that residues 
will be higher in the milk of cattle treated with oxfendazole than 
those in the milk of cattle treated with fenbendazole.
The milk withholding time for febantel in cattle is forty-eight 
hours.If febantel has similar plasma kinetics to fenbendazole and 
oxfendazole, and a similar tissue residue profile, then one can assume 
that milk residues of febantel would be similar to those after 
fenbendazole and oxfendazole treatment. If this was the case, it is 
very likely that residues of febantel in milk would persist longer than 
forty-eight hours, since residues of fenbendazole and oxfendazole in 
milk persisted beyond forty-eight hours.
Liver residues of benzimidazoles are more likely to be a problem,
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because of the persistence of metabolites which are known teratogens. 
Of all the drugs studied, albendazole, albendazole sulphoxide and 
oxfendazole are teratogenic. Albendazole sulphoxide is the major 
metabolite of albendazole and is more teratogenic than oxfendazole. The 
teratogenic dose of albendazole in man is not known, but it can be 
estimated from other species, the most sensitive being rabbits, sheep 
and rats, in which the plasma concentrations of albendazole sulphoxide 
which are associated with teratogenicity are in the order of 7 to 
10 yug/ml (Bogan, Personal Communication). In man, 400 mg of albendazole 
given to ten volunteers gave rise to a maximum concentration of
concentration of 0.20 yug/ml (Marriner et al., 1986). If it is assumed 
that the sensitivity of humans to the teratogenic effects of 
albendazole is similar to other sensitive species, a dose of 5.1g of 
albendazole (73 mg/kg for a 70 kg person) would be required to give a
concentration which is known to be teratogenic). This concentration is 
considered to be the lowest plasma concentration at which 
teratogenicity occurs. Therefore, a dose of 73 mg/kg of albendazole in 
humans could be considered to be the lowest-observed-adverse-effect 
level (LOAEL). The uncertainty factor (safety factor) chosen for major 
biological effects such as teratogencity, is 1,000. Therefore, for 
albendazole in humans, a LOAEL of 73 mg/kg corresponds to an acceptable 
daily intake (ADI) of 0.073 mg/kg/day (5.11 mg/day for a 70 kg person). 
Assuming a human will consume a maximum of 1 kg of liver per day, the 
acceptable residue of albendazole should be of the order of 5 yug/g. It 
would appear that most regulatory authorities, since the teratogenic
of albendazole sulphoxide in plasma, with a mean
plasma concentration of of albendazole sulphoxide (i.e. a
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dose for man is not known, err considerably on the side of caution and 
specify limits of, for example, 0.1 jig/g when setting withdrawal 
periods. However, albendazole and other benzimidazoles are probably 
limited by their solubility, and it is probable that increasing the 
dose does not give a proportional increase in concentrations in plasma 
and tissues. Therefore, this result is probably an underestimate of the 
acceptable daily intake of albendazole. In addition, teratogenicity 
occurs because of the existence of particular concentrations on a 
specific day in gestation. Variation from this timing produces much 
lowered teratogenicity. Therefore, the likelihood of an animal having a 
sufficiently high residue on a specific day of pregnancy would seem a 
remote possibility in general. Also, farmers are quite aware of the 
economics of anthelmintic treatment, and it is unlikely that an animal 
going to slaughter would be treated with an anthelmintic close to 
slaughter. Our survey of one hundred livers obtained from abattoirs 
would bear out the premise than an animal going to slaughter contains 
no residues of benzimidazole anthelmintics. Nevertheless, there is a 
risk and surveillance should be maintained to assess that risk. In 
addition, benzimidazoles are heat stable and would not be destroyed by 
the cooking of contaminated meat or liver. However, as discussed 
previously, the bioavailability of these compounds is likely to be very 
low in humans.
The analytical methods used to measure benzimidazoles and their 
metabolites were relatively simple and straightforward and appeared to 
work well in practice, with important biological concentrations being 
easily measured. With other anthelmintics, important biological
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concentrations are present for long periods after treatment compared to 
benzimidazoles. Therefore, residues of these anthelmintics may pose a 
greater problem to the consumer than benzimidazoles. For example, 
ivermectin is known to be lipid soluble and long-lasting, producing 
plasma concentrations for twenty-eight days and having efficacy for 
twenty-eight days. Also, residues of salicylanilide flukicides are 
known to persist for up to three months (Mohammed-Ali, 1985). It is 
therefore likely that animals will occasionally arrive at slaughter 
containing residues of these drugs. In addition, benzimidazoles are 
always administered orally, so they are-safer in the general respect 
that injected anthelmintics (e.g. ivermectin, salicylanilides) may give 
rise to very high local concentrations (to which the consumer may be 
exposed) which would not occur with orally administered anthelmintics.
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